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Skin melanocytes can give rise to different benign and malignant neoplasms. 
Discrimination of an early melanoma from an unusual/atypical benign nevus can 
represent a significant challenge. However, previous studies have shown that in 
contrast to benign nevi, melanoma demonstrates pervasive chromosomal aberrations. 
This substantial difference between melanoma and benign nevi formed the idea of 
exploiting this difference to discriminate between melanoma and benign nevi. Array-
comparative genomic hybridization (aCGH) is an approach that can be used on DNA 
extracted from formalin-fixed paraffin-embedded (FFPE) tissues to assess the entire 
genome for the presence of changes in DNA copy number. In this study,  high 
resolution, genome-wide single-nucleotide polymorphism (SNP) arrays were utilized 
to perform comprehensive and detailed analyses of recurrent copy number aberrations 
in 42 melanoma samples in comparison with 21 benign nevi. We found statistically 
significant copy number gains and losses within melanoma samples. Some of the 
identified aberrations are previously implicated in melanoma. Moreover, novel 
regions of copy number alterations were identified, revealing new candidate genes 
potentially involved in melanoma pathogenesis. Taken together, these findings can 
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The hypothesis of this study was that melanoma differs from melanocytic nevi by the 
presence of changes in DNA copy number. Finding these differences will  be 
exploited diagnostically to classify melanocytic tumors that are ambiguous based on 
histopathologic assessment. In addition to potential diagnostic applications, detailed 
analyses of recurrent aberrations will lead to the identification of genes associated 




1. Extract DNA from FFPE specimens with sufficient quantity and quality to be 
hybridized to SNP6.0 microarrays. 
2. Utilize the high resolution SNP6.0 microarrays to identify regions of copy 
number variations between melanoma and benign nevi samples.  
3. Utilize the high resolution SNP6.0 microarrays to reveal novel somatic copy 




TABLE OF CONTENTS 
 
I. INTRODUCTION …………………………………………………………..........   1 
            Melanoma Prevalence ……………………………………………………….  1 
            Diagnostic Difficulties ………………………………………………………  2 
            Current Diagnostic Techniques ……………………………………………..   2 
            Copy Number Variations in Melanoma versus Benign Nevi………………… 3 
            Array-Comparative Genomic Hybridization for more detailed analysis ……  4 
         Difficulties of DNA Extraction from FFPE tissues …………………………  5 
           Utilization of GISTIC to Detect Copy Number Aberrations ………………..  5 
        Summary of the Findings In This Study ……………………………………. 6 
II. MATERIAL AND METHODS ………………………………………………….  7 
            Specimen Collection and Preparation ……………………………………….. 7 
            DNA Isolation from FFPE Tissues…………………………………………... 8 
            Qiagen Extraction Method …………………………………………………... 8 
            Adaptive Focused Acoustics (AFA)-Based Extraction  Method …………... 16 
         Phenol-Chloroform-Isoamyl Alcohol Extraction Method …………...…….  21 
vi 
 
            Quality Control ……………………………………………………………    25 
            Array Comparative Genomic Hybridization to SNP6.0 Microarrays………. 26 
            Data Analysis ………………………………………………………………. 28 
            Affymetrix SNP6.0 Copy Number Inference Pipeline ……………………..  29 
            View the Segmented Copy Number Data By Using IGV ………………….  34 
            Genomic Identification of Significant targets in Cancer (GISTIC2.0)……..  35 
III. RESULTS AND DISSCUSSION ……………………………………………… 44 
            Specimen Collection and Preparation ……………………………………… 44 
            Improving the Quality of DNA Extracted from FFPE Specimens …………. 48 
            RAPD-PCR, A Predictor for aCGH Success of FFPE Samples …………… 54 
            Processing the Qualified DNA Through SNP 6.0 Protocol ………………..  56  
            Validating the Recurrent Copy Number Changes in Melanoma …………… 60 
            Genomic Identification of Significant Targets in Melanoma ………………. 66 
            GISTIC Analysis Reveals Novel Genes Potentially Involved in Melanoma . 96 
IIII. CONCLUSION………………………………………………………………… 98 
IIIII. REFERENCES………………………………………………………………..  99 
vii 
 
LIST OF FIGURES 
 
1. Workflow recommended for processing 48 samples through SNP6.0 protocol…. 27 
2. GISTIC Methodology …………………………………………………………… 36 
3. H&E Staining for Sections Taken from Melanoma Sample …………………….. 48 
4. Genomic DNA size range of samples extracted by three different methods ……. 50 
5. RAPD-PCR profile for 4 samples extracted by three different methods ………..  53 
6. RAPD-PCR profile for 12 different samples ……………………………………. 55 
7. Example of SNP6.0 PCR product of 4 different samples run on 2% agarose gel .. 57 
8. Examples of Enzymatic fragmentation performances run on 4% agarose gel…… 58 
9. APT analysis of Nsp1 and Sty1 Fragments ……………………………………..   60 
10. IGV copy number scale………………………………………………………..    61 
11. A comprehensive overview of the segmented copy number data ……………     62 
12. Copy number change of known amplified genes in melanoma ………………    64 
13. Copy number change of known deleted genes in melanoma………………...      66  
14. Row segmented copy number data obtained from SNP6 microarray analysis ..   68  
viii 
 
15. A driver mutation should occur in multiple tumors more often than would be 
expected by chance………………………………………………………………….. 69 
16. Statistically significant genomic amplifications identified by GISTIC………..   70 
















LIST OF TABLES 
 
1. Details of specimens used in this study…………………………………………    44 
2. Details of specimens used in the quest of improving DNA quality…………….    49 
3. Summary of the QC metrics for the methods comparisons. ……………………    51 
4. Description of the statistically significant amplified regions identified by 
GISTIC……………………………………………………………………………… 71   
5. Description of the statistically significant deleted regions Identified by GISTIC.. 78 











I. INTRODUCTION AND BACKGROUND: 
 
In the United States, skin cancer is the most common of all cancers [1]. Most cases of 
skin cancer are non-melanoma skin cancer. In fact, melanoma accounts for less than 
2% of skin cancer [1]. Melanoma is a cancer that arises from the malignant 
transformation of epidermal melanocytes, pigment-synthesizing cells of the skin. 
When melanoma escapes early detection, it becomes one of the most aggressive and 
highly lethal forms of cancers. Although it accounts for the minority of skin cancers, a 
large majority (75%) of skin cancer related-deaths are due to melanoma [1, 2]. The 
incidence and mortality of melanoma have increased dramatically in the last few 
decades [3]. The American Cancer Society estimates that about 73,870 people in 
United States will be diagnosed with melanoma in 2015 and about 9,940 people are 
expected to die from the disease. Importantly, the 5-year survival rate of melanoma 
depends on the stage of the disease when it is diagnosed. It can be as high as 98% 
when the melanoma is detected early before it spreads to the lymph nodes or other 
organs. When melanoma reaches the lymph nodes, the 5-year survival rate goes down 
to 62%, and to 15% when melanoma spreads to other organs [2]. Different factors are 
responsible for the increased risk of melanoma development. These factors include 
physical characteristics such as red hair, blue eyes, light complexion and presence of 
pigmented lesions. Moreover, environmental factors such as sun exposure are 
associated with the increase risk of melanoma. Yet, the genetic factor and families 
with strong history of the disease are the most important factors contributing to the 
increased risk of melanoma [4, 5].  
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The pigment-producing cells, melanocytes, can give rise to different benign 
(melanocytic nevi) and malignant (melanoma) neoplasms. Early diagnosis of 
melanoma is still the most effective way for long term survival and saving melanoma 
patients' lives from the disease [6].  In the majority of the cases, dermatopathologists 
can correctly diagnose and differentiate a melanocytic nevus from a malignant 
melanoma. However, dermatopathologists are aware of the diagnostic difficulties of a 
subset of melanocytic tumors that cannot be easily classified as benign or melanoma. 
These tumors have ambiguous histopathological features that overlap between 
melanocytic nevi and melanoma, where some benign melanocytic nevi, due to 
secondary changes, show unusual attributes that are more associated with melanoma 
diagnosis. Therefore, the pathology of melanocytic neoplasms remains as one of the 
most challenging and controversial areas in diagnostic histopathology [7]. The 
uncertainty and discordance among expert dermatopathologists in diagnosing 
melanocytic neoplasms have been shown in several studies [8-14]. The diagnostic 
uncertainty and the ambiguity of some melanocytic tumors results in melanoma 
misdiagnosis, which in turn can lead to melanoma overdiagnosis accompanied with 
increase in medical costs and unnecessary surgeries and stress. Conversely, melanoma 
underdiagnoses results in negligence of a lethal disease [6] that would have been 
imminently curable if resected earlier.   
Histopathological examination of hematoxylin and eosin (H&E)-stained tissue 
sections remains  the main approach for evaluating melanocytic tumors. However, due 
to the histopathological ambiguity of some melanocytic neoplasms, molecular 
diagnostic techniques have emerged in the field of dermatopathology as ancillary tests 
that can help in the diagnosis of melanoma. These molecular tests have shown 
promise in improving the differential diagnosis of melanoma. One of these molecular 
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diagnostic techniques that has been used intensively in melanoma diagnosis is 
immunohistochemical staining for melanocytic markers such as Melan-A (A103), S-
100 and HMB-45 [15-17]. More recently, cytogenetic analysis have been developed 
and become popular method in the area of distinguishing melanoma from benign nevi. 
For instance, using fluorescence in situ hybridization (FISH) assays as an adjunctive 
test in the diagnosis of ambiguous melanocytic tumors have been increasingly utilized 
in dermatopathology laboratories.  Several studies have shown the potential of the 
FISH assay as a successful discriminatory test that can distinguish between 
problematic melanocytic lesions [7, 18-20]. Currently, the most commonly used  
FISH assay employs a 4-probe panel targeting 4 loci (RREB1, MYB, centromere 6, 
and CCND1) on 2 different chromosomes. The 4-probes FISH has shown a sensitivity 
and specificity of 86.7% and 95.4% respectively [18]. Recent study has shown an 
improvement of the FISH assay by incorporating new probes that target 4 different 
chromosomes (CDKN2A on 9p21, RREB1 on 6p25, MYC on 8q24 and CCND1 on 
11q13) with increased sensitivity and specificity to 94% and 98% respectively [7]. 
 
Although the FISH assay was introduced as a diagnostic tool in the field of 
differential diagnosis of melanoma fairly recently, the principle of developing this 
assay was based on findings that existed over a decade ago. After the emersion of 
comparative genomic hybridization as a novel technique that can screen the entire 
genome for copy number changes in one experiments in 1992 [21], several studies (by 
Bastian and others) have revealed that the majority of melanomas differ from benign 
nevi in their genetic makeup. These studies demonstrated gain or loss of specific 
chromosomal segments and showed that the majority of melanomas harbor recurrent 
chromosomal copy number aberrations. With some exceptions such as in Spitz nevi, 
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these chromosomal rearrangements are rarely detected in melanocytic nevi [22-25]. 
Frequent genomic alterations known to occur in melanoma include gains at 1q, 6p, 7p, 
7q, 8q, 17q and 20q in conjunction with deletions at 6q, 8p, 9p, 9q, 10p, 10q, 11q and 
21q[22-24]. These fundamental differences in the pattern of genetic alterations 
between melanomas and benign nevi established the idea that copy number variations 
can be diagnostically valuable for histopathologically ambiguous melanocytic 
neoplasms. Therefore, developing diagnostic assays targeting these genetic 
differences, such as FISH assays, would help improve the differential diagnosis and 
prognosis of melanoma.  
Utilizing CGH as a research tool has been decidedly a huge advancement in the 
cancer research field. As previously mentioned, the use of CGH has enhanced our 
knowledge of the genetic alterations occurring in the melanocytic tumors. However, 
in melanoma, these genetic alterations tend to be broad copy number events spanning 
large genomic regions. Rationally, the frequent existence of changes in these genomic 
regions in melanoma, but not in the benign nevi, indicates the presence of critical 
melanoma-related genes within these regions. The task of uncovering such genes 
remains a challenge. Yet, significant progress in CGH technology and the 
development of newer, high-density, genome-wide single-nucleotide polymorphism 
(SNP) arrays have simplified this task and make it achievable.  The high-resolution 
microarrays allow for detection of more precise and smaller regions of specific copy 
number changes. The effectiveness of using these arrays in accurate identification of 
copy number alterations has been shown in various cancer studies [26-30]. Applying 
this high-resolution technique in melanoma has shown more detailed and recurrent 
amplifications and deletions of genomic regions containing important cancer genes. 
Among these genes are CDKN2A and PTEN in the statistically significant deleted 
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regions; BRAF, EGFR and CCND as the most frequently amplified genes [4, 31, 32]. 
Furthermore, good examples of the ability of these high-resolution microarrays in 
revealing potential cancer genes were demonstrated in identifying the current 
melanoma biomarker MITF gene [33] and the melanoma metastatic gene NEDD9 as 
well [34]. Therefore, these advances in array CGH technology have provided great 
opportunities to detect novel and previously unrecognized key driver genes that can 
help improve melanoma prognosis, diagnosis, and even developing targeted therapies. 
However, aCGH presents its own set of unique challenges.  DNA is required of 
sufficient quantity and quality to hybridize to arrays and provide meaningful results. 
The reliability and accuracy of this molecular test depends on our ability to obtain 
quality DNA from the same biomaterials that that are provided by pathologists. This 
is especially difficult for DNA from formalin-fixed paraffin-embedded (FFPE) 
tissues. Consequently, it is important to use efficient methods for the extraction of 
quality nucleic acids, especially when the available tissue sections are small and 
irreplaceable. In the course of this project, we compared DNA extracted from the 
same specimens by three different methods and found that the extraction method can 
significantly affect the quality and quantity of DNA obtained from a given specimen.     
Here, we report our investigation for chromosomal aberrations that can help in the 
identification of genomic targets for melanoma diagnosis and therapy. To detect 
genome-wide statistically significant copy number events, we analyzed high-density 
single-nucleotide polymorphism (SNP) array data of 42 melanoma samples compared 
with 21 benign nevi. We utilized a statistical method called genomic identification of 
significant targets in cancer (GISTIC) that allows of detection of genomic regions that 
have high probability to contain driver cancer genes [35, 36]. GISTIC has been 
6 
 
actively used in different cancer studies and has helped in the detection of different 
amplified and deleted genes [37-41].  
The 42 melanoma samples analyzed by GISTIC show 8 statistically significant 
amplifications and 32 deletions. Some of the identified aberrations are previously 
known in melanoma and being used in some of the diagnostic techniques to 
differentiate between melanoma and benign nevi. Furthermore, GISTIC analysis 
revealed novel regions of aberration harboring potential candidate genes involved in 

















II. MATERIAL AND METHODS: 
 
Specimen Collection and preparation: 
Following IRB review, melanocytic tumor  specimens (melanoma and benign nevi) 
were selected from a large archive of FFPE skin biopsies collected at a national 
dermatopathology laboratory (Dermatopathology Laboratory  of Central States, 
DLCS, Dayton, OH).  De-identified retrospective clinical data were obtained from 
clinical databases and patient health records software (Intellipath) at DLCS. Patients 
ranged in age from 14 to 90 years.  The biopsy specimens were collected between 
2001 and 2013, making their age range between 2 and 14 years. Specimens were 
stored in a temperature-controlled environment.   
For all experiments, 10 m thick sections were taken for each sample from paraffin 
blocks by using a microtome with disposable blades. Care was taken to avoid 
contamination between the specimens by changing gloves when handling the blocks, 
cleaning the microtome after cutting a block, and using fresh blades for each 
specimen. The sections were placed in a warm water bath to help mounting them on 
slides. Then, tissues were incubated overnight at room temperature to be air dried.  
The first and last sections from each block were stained with H&E staining to verify 
that the region of interest (consisting of cellular material) still presents and had not 
been exhausted.  For DNA extraction, tissues were scraped from slides using either 
sterile scalpel blades into 1.5 mL microcentrifuge tubes in case of Qiagen  and  
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phenol-chloroform extraction methods; or by using Covaris SectionPicks into Screw-
Cap microTUBES for the adaptive focused acoustics-based extraction method. The 
number of sections taken per sample varies between methods, as described below.
 
DNA isolation from FFPE tissues: 
To optimize the DNA quality and acquire DNA of sufficient length, purity, and 
“amplifiability for aCGH analysis, DNA isolation was carried out by comparing three 
different extraction methods for extracting quality DNA from FFPE tissues; Qiagen 
QIAamp DNA FFPE tissue kit, phenol-chloroform isoamyl alcohol extraction and 
Adaptive Focused Acoustics (AFA) - based extraction using the Covaris truXTRAC 
FFPE DNA kit. Metrics of quantity and quality were considered for each method. 
However, only the DNA extracted by column-based methods (Qiagen QIAamp DNA 
FFPE tissue kit and Adaptive Focused Acoustics (AFA) - based extraction using the 
Covaris truXTRAC FFPE DNA kit) was used for aCGH.  
Qiagen extraction method: 
The original protocol of the Qiagen QIAamp DNA FFPE tissue kit (QIAGEN GmbH, 
D-40724 Hilden) is as follows: 
1. Using a scalpel, trim excess paraffin off the sample block.  
2. Cut up to 8 sections 5–10 µm thick .If the sample surface has been 
exposed to air, discard the first 2–3 sections.  
3. Immediately place the sections in a 1.5 or 2 ml micro centrifuge 
tube and add 1 ml xylene to the sample. Close the lid and vortex 
vigorously for 10 sec. 
4. Centrifuge at full speed for 2 min at room temperature (15–25°C).   
9 
 
5. Remove the supernatant by pipetting. Do not remove any of the 
pellet.  
6.  Add 1 ml ethanol (96–100%) to the pellet, and mix by vortexing. 
The ethanol extracts residual xylene from the sample.  
7.  Centrifuge at full speed for 2 min at room temperature. 
8.  Remove the supernatant by pipetting. Do not remove any of the 
pellet. Carefully remove any residual ethanol using a fine pipet tip. 
9.  Open the tube and incubate at room temperature or up to 37°C. 
Incubate for 10min or until all residual ethanol has evaporated.  
10. Resuspend the pellet in 180 µl Buffer ATL. Add 20 µl proteinase 
K, and mix by vortexing.  
11. Incubate at 56°C for 1 h (or until the sample has been completely 
lysed). 
12. Incubate at 90°C for 1 h. The incubation at 90°C in Buffer ATL 
partially reverses formaldehyde modification of nucleic acids. 
Longer incubation times or higher incubation temperatures may 
result in more fragmented DNA. If using only one heating block, 
leave the sample at room temperature after the 56°C incubation 
until the heating block has reached 90°C.  
13. Briefly centrifuge the 1.5 ml tube to remove drops from the 
inside of the lid. If RNA-free genomic DNA is required, add 2 µl 
RNase A (100 mg/ml) and incubate for 2 min at room 
temperature before continuing with step 14. Allow the sample to 
cool to room temperature before adding RNase A.  
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14. Add 200 µl Buffer AL to the sample, and mix thoroughly by 
vortexing. Then add 200 µl ethanol (96–100%), and mix again 
thoroughly by vortexing. It is essential that the sample, Buffer 
AL, and ethanol are mixed immediately and thoroughly by 
vortexing or pipetting to yield a homogeneous solution. Buffer 
AL and ethanol can be premixed and added together in one step 
to save time when processing multiple samples. A white 
precipitate may form on addition of Buffer AL and ethanol. This 
precipitate does not interfere with the QIAamp procedure. 
15. Briefly centrifuge the 1.5 ml tube to remove drops from the 
inside of the lid.  
16. Carefully transfer the entire lysate to the QIAamp MinElute 
column (in a 2 ml collection tube) without wetting the rim, close 
the lid, and centrifuge at 6000 x g (8000rpm) for 1min.Place the 
QIAamp MinElute column in a clean 2ml collection tube, and 
discard the collection tube containing the flow-through. If the 
lysate has not completely passed through the membrane after 
centrifugation, centrifuge again at a higher speed until the 
QIAamp MinElute column is empty. 
17. Carefully open the QIAamp MinElute column and add 500 µl 
Buffer AW1 without wetting the rim. Close the lid and centrifuge 
at 6000 x g (8000 rpm) for 1 min. Place the QIAamp MinElute 
column in a clean 2ml collection tube, and discard the collection 
tube containing the flow-through.  
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18. Carefully open the QIAamp MinElute column and add 500 µl 
Buffer AW2 without wetting the rim. Close the lid and centrifuge 
at 6000 x g (8000 rpm) for 1 min. Place the QIAamp MinElute 
column in a clean 2ml collection tube, and discard the collection 
tube containing the flow-through. Contact between the QIAamp 
MinElute column and the flow-through should be avoided. Some 
centrifuge rotors may vibrate upon deceleration, resulting in the 
flow-through, which contains ethanol, coming into contact with 
the QIAamp MinElute column. Take care when removing the 
QIAamp MinElute column and collection tube from the rotor, so 
that low-through does not come into contact with the QIAamp 
MinElute column. 
19. Centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min to dry 
the membrane completely. This step is necessary, since ethanol 
carryover into the elute may interfere with some downstream 
applications.  
20. Place the QIAamp MinElute column in a clean 1.5 ml 
microcentrifuge tube (not provided), and discard the collection 
tube containing the flow-through. Carefully open the lid of the 
QIAamp MinElute column and apply 20–100 µl Buffer ATE to 
the center of the membrane. 
 
Important: Ensure that Buffer ATE is equilibrated to room 
temperature. If using small elution volumes (<50 µl), dispense Buffer 
ATE onto the center of the membrane to ensure complete elution of 
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bound DNA. QIAamp MinElute columns provide flexibility in the 
choice of elution volume. Choose a volume according to the 
requirements of the downstream application. The volume of elute will 
be up to 5 µl less than the volume of elution solution applied to the 
column.  
21. Close the lid and incubate at room temperature for 1 min. 
Centrifuge at full speed (20,000 x g; 14,000 rpm) for 1 min, 
incubating the QIAamp MinElute column loaded with Buffer 
ATE for 5min at room temperature before centrifugation 
generally increases DNA yield. 
 
A previous lab member had modified this original protocol of the Qiagen 
FFPE DNA Tissue kit in order to optimize the results. The modifications for 
the original protocols included:1) Increasing the number of 10 um sections 
from 10 to 20-24 sections, 2) mounting the sections on glass slides first to be 
air dried, instead of placing the ribbon of FFPE sections directly from the 
microtome into the microcentrifuge tubes, 3) increasing the volumes of the 
lysis buffer and proteinase K, and 4) increasing the digestion time with 
proteinase K from 1 hour to overnight incubation (up to 16 hours).  The 
modified protocol was as follows: 
1. Take 20-24  10µm thickness sections off the glass slides into 




2. Add 1 ml of 100% xylene, Vortex and centrifuge at 20,000xg for 5 
minutes. Remove supernatant. 
3. Wash tissues with 500µl of 100% ethanol, vortex and centrifuge at 
20,000xg for 3 minutes then remove supernatant. 
4. Wash tissues for the second time with 500µl of 75% ethanol, 
vortex and centrifuge at 20,000xg for 3 minutes then remove 
supernatant. 
5. Wash tissues for third time with 500µl of 50% ethanol, vortex and 
centrifuge at 20,000xg for 3 minutes and then remove supernatant. 
6. Allow tissue to dry before processing. 
7. Add 300µl buffer ATL to dried tissue. 
8. Add 100µl proteinase K and mix by vortexing. 
9. Incubate overnight (8-12 hours, never longer than 16 hours) at 
56˚C. 
10. Add 400µl buffer AL to the sample and mix by inversion. 
11. Incubate at 70˚C for 10 minutes. 
12. Add 400µl ethanol to the sample and mix by inversion. 
13. Pipet mixture into DNeasy Mini Spin Column then centrifuge at 
6000xg for 1 minute. Discard the flow through. 
14. Add 500µl wash buffer AW1, then centrifuge at 6000xg for 1 
minute. Discard the flow through. 
15. Add 500µl wash buffer AW2 then centrifuge at 6000xg for 1 
minute. Discard the flow through. 
16. Add 500µl wash buffer AW2 again, then centrifuge at 6000xg 
for 1 minute. Discard the flow through. 
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17. Replace flow through tube with clean tube, then centrifuge at 
20,000xg for 3 minutes to remove any residual ethanol from the 
spin column. 
18. Replace flow through tube with clean micro centrifugetubes. 
19. Add 100µl buffer ATE, incubate at room temperature for 5 
minutes. 
20. Centrifuge at 20,000xg for 1 minute. 
 
When we used this modified protocol, we noticed that the DNA yield still low, 
and that mainly was because that some tissues (during the suggested digestion 
time) are not completely digested. Therefore, we have optimized the protocol 
by extending the digestion time from 16 hours to 72 hours. Moreover, instead 
of adding 100 l of proteinase K at one time, the proteinase K was added 
partially by adding 40 l first, then 30 l at 24 hours, and another 30 l at 48 
hours. The current modified and optimized protocol of the Qiagen FFPE DNA 
Tissue kit is as follows: 
1. Cut 24 FFPE sections of 10 µm thickness for each DNA 
extraction and mount them on glass slides . 
2. After scraping the tissues from the slides into microcentrifuge 
tubes, incubate tissue samples in water bath  at 60˚C for 30 
minutes. 
3. Wash tissues in microcentrifuge tube twice in 1 mL xylene, 
vortex and centrifuge at 20,000xg for 3 minutes each time. 
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4. Wash tissues in a descending concentration of ethanol (100, 75%, 
and then 50%). For each time, vortex and centrifuge at 20,000xg 
for 3 minutes and then remove supernatant . 
5. Allow tissues to dry in the microcentrifuge tubes completely 
before proceeding to next step. 
6. Add 300 l Qiagen buffer ATL plus 40 l proteinase K 
(20mg/mL, 5 PRIME Inc., Gaithersburg, MD, USA) to dried 
tissue and mix by vortexing, incubate at 56 ºC for 72 hours. 
7. Add an additional 30 l proteinase K at 24 hours and another 30 
l at 48 hours of incubation.  
8. After 72 hours digestion, add 400µl buffer AL to the sample, mix 
by inversion (never vortex after the incubation, which can 
degrade the DNA).   
9. Incubate at 70˚C for 10 minutes. 
10. Add 400µl ethanol to the sample and mix by inversion. 
11. Pipet sample mixture into Qiagen DNeasy Mini Spin Columns, 
then centrifuge at 6000xg for 1 minute. Discard the flow through. 
12. Add 500µl wash buffer AW1, centrifuge at 6000g for 1 minute 
and discard the flow through  . 
13. Add 500µl wash buffer AW2, centrifuge at 6000g for 1 minute 
and discard the flow through  . 
14. Add 500µl wash buffer AW2 again, then centrifuge at 6000xg 
for 1 minute. Discard the flow through. 
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15. Replace flow through tube with clean tube, then centrifuge at 
20,000xg for 3 minutes to remove any residual ethanol from the 
spin column. 
16. Replace flow through tube with clean microcentrifuge tube. 
17. Add 100µl buffer ATE, incubate at room temperature for 5 
minutes. 
18. Centrifuge at 20,000xg for 1 minute. 
 
Adaptive Focused Acoustics (AFA)-based extraction method: 
One of the advantages of using this method is that it requires less input 
material (8-10 sections) compared to the other two methods. Here, the Slides 
are warmed up on a heat block at 37 °C for 30 seconds to facilitate scraping 
the tissues.  FFPE tissues are then scraped from the slides, trying to avoid 
paraffin, using Covaris SectionPicks into Screw-Cap microTUBES provided 
by Covaris.  The DNA extraction was performed Per manufacturer’s 
instructions following the protocol suggested by Covaris (Woburn, MA, USA) 
in the truXTRAC FFPE DNA kit (“protocol C”) on a Covaris M220 Focused-
Ultrasonicator. The protocol is as follows: 
1. Open microTUBE Screw-Cap, add 100 µl Tissue SDS Buffer 
into microTUBE and load FFPE tissue (section or core). Affix 
Screw-Cap back in place.  
2. Process the sample using the settings provided in the protocol to 
dissociate the paraffin while simultaneously rehydrating the 
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tissue. During the AFA process it is normal for the solution to 
turn milky white as the paraffin is emulsified. 




3. Open Screw-Cap microTUBE, add 20 µl of Proteinase K solution 
to the sample and affix Screw-Cap back in place. 
4. Process the sample using the settings provided to properly mix 
Proteinase K with the sample. 
 Proteinase K mixing settings 
 
5. Protein digestion at 56°C. Insert the required number of Heat 
Block microTUBE Adapters into a Heat Block and set the 
temperature to 56°C.  
6. Load the microTUBE into the adapter once the heat block has 
reached its set point.  
7. An incubation time of 1 hour at 56°C is sufficient for sections 10 
µm or less in thickness; 12-hour (i.e. overnight) incubation 
should be used for larger samples, such as 25 µm sections and 
cores. If the digestion is incomplete after 12 hours, add 20 µl of 
Proteinase K solution, mix, and incubate for 1 more hour. Here, 
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the homogenized tissue was digested for 2 hours instead of 1 
hour in proteinase K provided by Covaris kit. 
8. Incubate the samples at 80°C for 1 hour to reverse formaldehyde 
crosslinks. 
9. Insert the required number of Heat Block microTUBE Adapters 
into a Heat Block and set the temperature to 80°C. Load the 
microTUBE into the adapter once the heat block has reached its 
set point. 
10. If using the same heat block for both the 56°C & 80°C 
incubations, the microTUBE should be stored at room 
temperature until the heat block reaches 80°C.  
11. Transfer the sample to a clean 1.5 ml microcentrifuge tube.  
12. Optional: The sample can be treated with RNase A to remove 
RNA before DNA purification. Add 5µl of RNase A solution and 
incubate for 5 minutes at room temperature.  
-Then DNA purification: 
Set heat block to 70°C and preheat the required volume of Buffer BE 
in a 1.5mL microfuge tube: (number of samples x 100 µl x 1.1)  
1. Add 140 µl Buffer B1 to your sample and vortex thoroughly.  
2. Add 160 µl ethanol (>96%) to the sample and vortex thoroughly. 
3. Centrifuge at 10,000 x g for 2 minutes at room temperature. After 
centrifugation much of the paraffin will have formed a white 
layer, floating on top of the liquid.  
4. Place a Purification Column into a provided Collection Tube. 
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5. While holding the sample tube at about the same angle as in the 
rotor, use a pipette to slowly recover the liquid layer, and transfer 
to the column. Transfer of a small amount of paraffin particles to 
the column is acceptable and will not interfere with the DNA 
purification.  
6. Spin the assembly at 11,000 x g for 1 minute.  
7. Discard the flow-through and place the Column back in the 
Collection Tube.  
8. 1st wash: Add 500 µl Buffer BW. Spin the assembly at 11,000 x 
g for 1 minute.  
9. Discard the flow-through and place the Column back in the 
Collection Tube. 
10. 2nd wash: Add 600 µl Buffer B5. Spin the assembly at 11,000 x 
g for 1 minute.  
11. Discard the flow-through and place the column in a new 
Collection Tube  
12. Dry column: Spin the assembly at 11,000 x g for 1 minute. 
13. Elute DNA - 1st step: Place the Purification Column into a new 
1.5 ml microcentrifuge tube and add 50 µl pre-warmed Buffer 
BE (70 °C) to the center of the column. Incubate at room 
temperature for 3 minutes. Spin the assembly at 11,000 x g for 1 
minute.  
14. Elute DNA – 2nd step: Add a second aliquot of 50 µl pre-
warmed Buffer BE. Incubate again at room temperature for 3 
minutes. Spin the assembly at 11,000 x g for 1 minute.  
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15. DNA is eluted in 100 µl Buffer BE. 
 
In order to get enough concentration for the SNP 6.0 protocol, 
some of the samples were concentrated by speed vac . For each Sty 
and Nsp restriction enzyme digestion, an amount of genomic DNA 
input of 500 ng in a volume of 10 µl is required. Therefore, DNA 
samples with low concentrations (<50 ng/µl) need to be 
concentrated in order to get the required amount of DNA (500 ng) 
in 10 µl. The Speed vac protocol used to concentrate the DNA is as 
follows: 
1. For samples with low DNA concentration, calculate the amount 
of  DNA (µl) required   to obtain 500 ng of DNA . For example,  
sample with DNA concentration of 10 ng/µl, 50 µl from that 
sample is needed to make 500 ng of DNA (10 ng x 50 µl = 500 
ng of DNA). 
2.  Put DNA from each sample in a separate micro centrifuge tube 
for speed vac. 
3. Equalize the volume in all speed vac tubes by bringing the 
volume up with nuclease-free water to have a similar volume in 
all tubes. 
4. Make a separate tube with 10 µl of water to be used as a control . 
5. Speed vac the DNA on low drying rate until it is close to 10 µl 
(compare to the control tube).  





Phenol-chloroform-isoamyl alcohol extraction method: 
The Phenol-chloroform-isoamyl alcohol extraction is a well-known nucleic acids 
extraction method that, differently than the previously described two extraction 
methods, is a non-column based extraction method. It depends mainly on using some 
chemicals such as phenol-chloroform-isoamyl alcohol to separate the nucleic acids 
from other cellular components after lysing the tissues, and then precipitating the 
DNA with ethanol.  We used this protocol as was described by Isola et al [42] with 
including some modifications. The protocol described by Isola et al. is as follows: 
1. 20 to 30 5µm sections were de-paraffinized in Eppendorf  tubes 
(2 x 1 ml xylene for 10 minutes each and 2 x 1 ml 100% ethanol 
for 10 minutes each). 
2. After air drying at room temperature, samples were suspended in 
1 ml DNA extraction buffer (0.3 mg/ml proteinase K (Sigma, St. 
Louis, MO), 100 mmol/L NaCI, 10 mmol/L Tris-HCI pH 8, 25 
mmol/L EDTA pH 8, and 0.5% sodium dodecyl sulfate) and 
were incubated with shaking at 55˚C overnight.  
3. Additional proteinase K (10µl from 20 mg/ml stock solution) 
was added 24 hours and 48 hours later for a total incubation time 
of 72 hours.  
4. A 500µl of the digested sample were mixed with 500 µl phenol –
chloroform-isoamyl alcohol 25:24:1 (Fisher Scientific, Fair 
Lawn, New Jersey, USA) and incubated at room temperature for 
10 minutes and then centrifuged.  
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5. DNA in the top (aqueous ) layer was collected and precipitated 
with 250 µl of 7.5 mol/L ammonium acetate and 1 ml of ice-cold 
100% ethanol.  
6. DNA was pelleted by centrifugation (14,000 rpm for 20 
minutes). 
7. Glycogen (0.1 mg/ml; Sigma) was added before centrifugation as 
a carrier to increase the volume of the pellet.  
8. DNA was dissolved overnight in 20 to 40 µl of TE buffer (10 
mmol/L Tris, 1 mmol/L EDTA) 
 
 
We used the same protocol but with some modifications. The modified protocol is as 
follows:  
1. 24 sections of 10 m thickness were used from each FFPE 
sample. FFPE sections were scraped from the air-dried slides 
using sterile scalpel blades into 1.5 mL microcentrifuge tubes.   
2. Add 1 ml of xylene to each tube, vortex vigorously and incubate 
for 10 min, centrifuge for 5 min at 20,000 x g. Discard the 
supernatant. 
3. Repeat step 2 again. 
4. Washing the xylene by Add 1 ml of 100% ethanol, vortex, 
incubate for 10 min, centrifuge for 3 min at 20,000 x g. Discard 
the supernatant. 
5. Repeat step 4 again. 
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6. Add 1 ml of 75% ethanol, vortex, incubate for 10 min, centrifuge 
for 3 min at 20,000 x g. Discard the supernatant. 
7. Air dry the tubes at room temperature by inverting them on a 
clean tissue. 
8. Add 985 µl of DNA extraction buffer (described above) and 15 
µl of 20 mg/ml stock solution of proteinase k. 
9. Incubate tubes on water bath shaking incubator at 57˚C and 
adjust the speed of shaking to 3-3½ rpm. 
10. Keep checking the water level in the shaker regularly (the water 
level will decrease over time due to evaporation).  
11. Add additional 10 µl proteinase k to each tube after 24 hours and 
mix by vortex very lightly. 
12. Add another 10 µl of proteinase k to each tube after 48 hours and 
mix by flipping the tubes (to avoid DNA degradation, do not 
vortex  the samples at this point). 
13. After 72 hours, incubate the samples at 95˚C for 40 min to 
reverse formaldehyde crosslinks. Then, cool the samples down to 
room temperature before proceeding. 
14. Mix 500 µl of the digested sample with 500 µl of the phenol- 
chloroform-isoamyl alcohol 25:24:1, then mix by shaking the 
tubes.  
15. 2 layers will form in each tube; incubate the tubes for 5 min at 
room temperature. 
16. Centrifuge at 20,000 rcf for 10 min at 4˚C. 
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17. Transfer the top aqueous layer (which has the DNA) to a new 
tube. 
18. Add an equal amount of chloroform to the DNA in the new tube 
(for example: 100 l of aqueous layer with  100 l of 
chloroform), mix by flipping the tubes, incubate for 5 min at 
room temperature and centrifuge at 20,000 rcf for 10 min (the 
chloroform will wash the residual phenol).  
19. Transfer the top layer into a new tube. Discard the organic 
solvent by disposing them in the chemical waste container. 
20.  Add 1 ml of ice cold 100% ethanol to each tube.  
21. Add 250 µl of ammonium acetate and mix by flipping the tubes 
for few times. 
22. Incubate the tubes in -80˚C for 35 min or in -20ºC overnight, 
then centrifuge at 14,000 rpm for 20 min at 4˚C. 
23. Discard the supernatant carefully without breaking the pellet.   
24. Wash the pellet by adding 500 µl 70% ethanol, invert several 
times without breaking the pellet, and spin at maximum speed at 
4˚C for 5 min.  
25. Aspirate the supernatant carefully without breaking the pellet.  
26. Dry the pellet completely by leaving the tubes open at room 
temperature for 5-10 min. It is important to make sure that there 
is no ethanol in the tube before dissolving the pellet.   
27. Add 40 l of TE buffer (Tris 10Mm, EDTA 1Mm pH8.0)  and 

















 ratios.  For a more accurate quantitation, the 
Qubit® dsDNA BR Assay Kit (Thermo Fisher Scientific, Waltham, MA) was used to 
check the concentrations of dsDNA for all samples.   
 
DNA fragment sizes: 
After DNA extraction and quantification, genomic DNA fragment sizes were first 
estimated by agarose gel electrophoresis of  250 ng DNA using 1% agarose gels (90 
mM Tris –borate, 2 mM EDTA, 1% agarose).  Samples with visible DNA fragments 
as large as 23,000 base pairs (bp) were used.  
 
Randomly Amplified Polymorphic DNA PCR (RAPD-PCR): 
RAPD-PCR was used as a quality control step to directly assess the ability of each 
sample to produce high molecular weight amplicons (“amplifiability”) and be ideal 
for SNP6.0 protocol (SNP6.0 success indicator). RAPD-PCR was performed as was 
described by Siwoski A et al [43]. RAPD-PCR reactions were carried out in a 20 µL 
volume containing 25 ng DNA and using 10µl of GoTaq 2X Green Master Mix 
(Promega, Madison, WI USA). PCR was performed in 0.2 mL tubes in a GeneAmp 
PCR System 9700 thermocycler (Life Technologies, Carlsbad, CA, USA). Two 
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different sets of primers were used for RAPD-PCR and were generated by Eurofins 
MWG Operon Inc (Huntsville, AL, USA).  Sequences for the primer pairs and cycling 
parameters were as follows: 5’-AATCGGGCTG-3’ and 5’-GAAACGGGTG-3’, 94C 
for 2.5 minutes,  then 45 cycles of 1 minute 94C, 1 minute 55C and 2 minutes 72C, 
then 7 minutes 72C and holding at 4C; or 5’- TGTGCCCAGTGAAGACTCAG-3’ 
and 5’- GAGTGAGCGGAGAGGGAACT-3’, 45 cycles of 94° C for 1 minute, 35° C 
for 1 minute, and 72° C for 2 minute.  PCR products were resolved on 3% TBE 
agarose plus SYBR Safe dye (Life Technologies).  Gels were visualized with a GE 
ImageQuant LAS-3000 camera (GE Healthcare Life Sciences, Piscataway, NJ, USA). 
 
 
Array Comparative Genomic Hybridization to SNP6.0 Microarrays: 
Samples with good quality and quantity were processed and hybridized to the SNP6.0 
microarrays through SNP6.0 protocol to generate data for copy number analysis. A 




Figure 1: ) Workflow recommended for processing 48 samples through SNP6.0 protocol. 
 
The detailed SNP6.0 protocol is described in Affymetrix Genome-Wide Human SNP 
Nsp/Sty 6.0 User Guide. The SNP6.0 protocol was performed as suggested in the 
original protocol, but a few modifications were included in order to optimize the 
results. These modifications included: 
1. Increase in the input amount of DNA from 250 ng per restriction enzyme 
(Nsp1 and Sty1) to 500 ng each. 
2. The number of PCR reactions was doubled from the suggested three for 
Sty1 and four for Nsp1 to six for Sty1 and eight for Nsp1.  It is important 
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to note that the number of reactions was increased; the number of cycles 
in each reaction remained the same. The additional PCR reactions were 
combined as in the standard protocol. 
3. PCR cleanup was performed using isopropanol extraction (refer to 
Affymetrix User Bulletin 2: Improvements to step 7 of the SNP Assay 
6.0, PCR cleanup, using an isopropanol precipitation method, P/N 
702968 Rev. 1). 
  
The Hybridization and scanning of the arrays followed the manufacturer’s protocol.  
  
Data analysis: 
After washing, staining, and scanning the microarrays, CEL files and other files such 
as CHP and ARR files will be generated. CEL files are the files used for copy number 
analysis through GenePattern. CEL files contain the raw intensity values of the 
individual probes on the arrays. These intensity values are normalized and then 
compared to intensity of the same probes of control samples (should have diploid 
normal copy number) to produce positive and negative values indicating copy number 
gain or loss at a specific genomic region. To find differences between melanoma and 
benign nevi in copy number changes, data generated from a set of 42 melanoma 
samples were compared to data generated from  21 benign nevi samples. The analysis 







I. Affymetrix SNP6 Copy Number Inference Pipeline. 
 
The Copy Number Inference Pipeline is a method in GenePattern from the Broad 
Institute (Massachusetts Institute of Technology, Cambridge, MA) that takes 
Affymetrix SNP6 CEL files and process them in a pipeline consists of different 
modules for data processing and analysis to generate segmented copy number calls for 
each sample [44, 45].  DNA copy number was estimated probe set-wise by comparing 
the normalized signal from 42 melanoma samples to data generated from 21 benign 
samples that were used as a reference. The pipeline first uses SNPFileCreator_SNP6 
module to normalize all of the SNP arrays by adjusting the raw intensity values from 
the SNP6 array so that they can be compared with other arrays. The second step is to 
convert intensity measurements into copy number calls by using the 
CopyNumberInference module. Then the copy number noise was calculated and then 
the copy number calls were de-noised with the RemoveCopyNumberOutliers module 
that removes probes that are outliers, which have radically different copy number calls 
than their hg19-adjacent neighbors. The Tangent normalization algorithm then 
reduced the noise further by subtracting out variation seen in a pre-defined set of a 
panel of more than 3000 blood normals from the Cancer Genome Atlas (TCGA). This 
exclusion of the germline CNVs is particularly important for algorithms that identify 
somatic alterations that are statistically significant such as GISTIC. The copy number 
data then were segmented by using the CBS (Circular Binary segmentation) algorithm 
that identifies regions in the genome that, in spite of noise, probably have a uniform 
underlying copy number. It compresses the values from a set of adjacent probes into a 
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single value for that interval [46]. The output of this pipeline (the segmented copy 
number calls) can then be used to run GISTIC to find the statistically significant copy 
number variations, as will be described further in this section.  
  
Here are step-by-step instructions for running copy number analysis through the 
CopyNumberInferencePipeline in GenePattern:  
1. An account is needed to use the GenePattern public sever, which is 
available at http://genepattern.broadinstitute.org/gp/pages/login.jsf. 
2. Register an account, and then sign in. 
3. After signing in, in the Modules panel on the left side of the screen, 
search and locate the CopyNumberInferencePipeline and select it. One 
easy way to do this: type the first few characters of the name into the 
search box and click on CopyNumberInferencePipeline  when it appears 
in the list of matching analyses. 
4. GenePattern will display the CopyNumberInferencePipeline  parameters. 
5. For the SNP6 cel files parameter, click the Upload File button and load 
the SNP6 cel files file (step 6 below explains the preparation of the SNP6 
cel files file). 
6. How to prepare the "SNP6 cel files" file:  
 Compress (or zip) all of the cel files that are going to be analyzed  (the 
tumor (melanoma) and the control samples (benign nevi) ) in one zip 
file.  
 Name the file as "snp6_sample_data".  
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 The zip file should only have the cel files that are being analyzed and 
match the sample information in the Sample Info File (see step 7). 
Having any file other than the cel files in the zip file will cause an error 
when running the pipeline. 
7. For the Sample Info File parameter, click the Upload File button and 
load the Sample Info File (step 8 below explains the preparation of the 
Sample Info File file). 
8. How to prepare the " Sample Info File" : 
This is a text file containing information about the samples. This 
information includes the array names, the gender of the patients, 
specification of the samples as either tumor or normal (control), and an 
indication that the normal (benign nevi) are diploid or not.  
 Use Microsoft Excel to prepare this file. 
 Four columns are required in this file. Name the first column as "Array", 
the second column as "Gender", the third column as "Tumor/Normal" 
and the fourth column as "Birdseed_normals". 
 In the first column (Array), list all of the array names that are being 
analyzed. The array names are the cel file names. Make sure to delete the 
".CEL" extension from the name. For example: if the array name is 
"20111201_A8_M27_(GenomeWideSNP_6).CEL"  it should be listed in 
the excel file as "20111201_A8_M27_(GenomeWideSNP_6)". 
 In the second column (Gender), indicate the samples gender as "M" for 
male, and "F" for female. The samples gender can be acquired from the 
samples clinical data from the clinical databases and patient health 
records software (Intellipath) at DLCS.  
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 In the third column (Tumor/Normal), all of the sample that are used as a 
control  should be indicated as "Normal" and other (test) samples should 
be indicated as "Tumor".  The samples that are indicated as Normal will 
be used as a baseline to which the tumor samples will be compared.  In 
this study, the benign nevi samples were used as a control samples to 
form a baseline, and the melanoma samples were compared to these 
benign nevi samples. The pipeline requires minimum of ten normal 
samples to perform the analysis.  
 In the fourth column (Birdseed-normal), put Y (for Yes) for  all of the 
normal "control" samples, and leave it blank (for No) for all of the tumor 
samples.  
 Make sure that there is no space in the array names, because that can 
cause an error when running the pipeline. 
 Save the file as a text file. To do so, in Excel, click on File, then Save 
As, then name the file as ''snp6_sample_data.sif", then click on Save as 
type,  then locate and select the type "Text (Tab delimited)", then click 
Save. 
9. For the Include CNVs parameter, select output without CNVs. This 
selection helps the algorithm to subtract out variation seen in a pre-
defined set of a panel of more than 3000 blood normals from the Cancer 
Genome Atlas (TCGA) along with the normals that are in the current 
batch. This exclusion of the germline CNVs is particularly important for 
algorithms that identify "somatic" alterations that are statistically 
significant such as in GISTIC. 
33 
 
10. For the genome annotation parameter, select hg19 (human genome build 
19). 
11. Lastly, click run to start the analysis. 
 
GenePattern sends the analysis job to the GenePattern server and displays the Job 
Status page. The running time depends on the number of samples being analyze (it 
can take days to run the analysis). 
 
Once the job is completed, GenePattern will display the results page, where many 
different output files will be shown. There are two important output files: 
 
1. "cbsResult.seg" file. It is the segmentation file that has the segmented 
copy number data for all of the samples identified by the CBS 
segmentation algorithm. It is a six-column, tab-delimited (text) file; the 6 
columns are identified as: Sample, Chromosome, Start, End, 
Num_Probes, and Segment-Mean.   
2. "snp6_sample_data.pip3avg.log_mdQUAD" file. It is a CN file that 
contains sorted SNPs and raw copy number value per probe.  It also 
identifies the probe names and positions in the original dataset before 
segmentation. The first three columns of this file are identified as: 
Marker, Chromosome, and physical position. The rest of the columns 
have the array names. This file will be used to create the Markersfile for 





Viewing the segmented copy number data: 
The segmented data that are generated from the segmentation algorithm (CBS) and 
stored in the cbsResult.seg file can be viewed and explored  by using  the Integrative 
Genomics Viewer (IGV). IGV is a high-performance visualization tool for interactive 
exploration of large, integrated genomic datasets [47, 48]. Using IGV to visualize the 
segmented data is useful for examining a genomic region of interest or  specific genes 
to see if they are affected by copy number change. The steps to visualize the data in 
the IGV are:  
1. IGV needs to be downloaded first. Go to the IGV downloads page: 
http://www.broadinstitute.org/igv/download. 
2. When prompted, register or log in as requested. You must register to 
download IGV. 
3. After logging in, in the downloads page, under the Java Web Start 
option, Click the launch icon for the option that is suitable for your 
system (Mac or Windows, the size of the memory). 
4. Save the IGV application. 
5. Go to the IGV application that was downloaded and start it. If the system 
displays messages about trusting the application, confirm that you trust 
the application and click Run. 
6. In IGV interface, go to File and then select "Load from File". 
7. Load the cbsResult.seg file. The IGV will display the segmented data for 




8. Now, the segmented data can be explored either by choosing the 
chromosome of interest or searching for a specific gene by typing the 
gene name in the search box. 
 
II. Genomic Identification of Significant targets in Cancer (GISTIC2.0). 
GISTIC  is a statistical method (also from GenePattern) that identifies  likely driver 
somatic copy number alterations that drive cancer pathogenesis; and that  by 
evaluating the frequency and amplitude of observed copy number events that are more 
frequent than would be expected by chance [35, 36].  GISTIC identifies significant 
alterations by two steps (Figure 2). First, GISTIC computes a statistic G score that 
considers the frequency F of the occurrence and the average amplitude A of the 
aberration (for example: the number of genomic region copies that are amplified or 
deleted) with higher score given to homozygous deletions or high level gene copy 
number amplification because they are less likely to take place by chance. Therefore, 




) represents the frequency of a genetic 
aberration (amplifications or deletions) seen at that locus across a set of samples, 
multiplied by the average (increase or decrease) in the log2 ratio in the region of 
aberration; G= F x A. GISTIC G-score, can be defined as : 
 
 
for marker i, sample log2 copy ratios aij, and copy-ratio threshold Ɵ, is equivalent to 
multiplying the frequency of alteration by the mean amplitude in altered samples. 
Second,  GISTIC determines the statistical significance of each computed metric G by 
comparing it to a background score metric (represents the results that would be 
expected by chance-null hypothesis) using a permutation test that is based on the 
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overall pattern of aberrations seen across the entire genome.  A peak region is 
reported at each statistically significant genomic region of aberration and known 
genes located at that region are listed. GISTIC performs false discovery rate control 
where G-scores are compared against a null  model, and regions with q–values below 
0.25 are considered statistically significant. 
 
Figure 2: GISTIC methodology. After identifying the locations and magnitudes (as log2 signal 
intensity ratios) of chromosomal aberrations in multiple tumors (Left), GISTIC assigns each 
genomic marker with a G score that is proportional to the total magnitude of aberrations at each 
location (Upper Center). Additionally, by permuting the locations in each tumor, GISTIC 
identifies the frequency with which a given score would be obtained if the events were due to 
chance and therefore randomly distributed (Lower Center). A significance threshold (green line) 
is determined such that significant scores are unlikely to occur by chance alone. Alterations are 
considered significant if they occur in regions that surpass this threshold (Right). 
 
 
GISTIC can be run on GenePattern with similar steps of running the 
CopyNumberInferencePipeline, but with more parameters to take into account:  
1. Sign in to GenePattern at 
http://genepattern.broadinstitute.org/gp/pages/login.jsf. 
2. After signing in, in the Modules panel on the left side of the screen, 
search and locate the GISTIC2.0 and select it. One easy way to do this: 
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type the first few characters of the name into the search box and click on 
GISTIC_2.0  when it appears in the list of matching analyses. 
3. GenePattern will display  the GISTIC2.0 parameters. 
4. For the refgene file parameter, select hg19 (human genome build 19). 
5. For the seg file parameter, click the Upload File button and load the 
cbsResult.seg file (step 6 below explains the preparation of cbsResult.seg 
for GISTIC).  
6. How to prepare the "cbsResult.seg" for GISTIC: 
 This cbsResult.seg file is the same file the was generated by the 
CopyNumberInferencePipeline, and it is the same file that is uploaded to 
IGV.  This file has segmented data for both the control (benign nevi) and 
tumor (melanoma) samples. But for GISTIC to find the statistical 
significant copy number changes in the melanoma samples, only the 
segmented data of the tumor (melanoma) samples are needed. Therefore, 
the segmented data of the control (benign nevi) need to be removed from 
the cbsResult.seg before loading it to GISTIC. To remove the segmented 
data of the control samples: 
 Open the cbsResult.seg file and copy all of the data in the file (click 
CTRL+A to highlight all of the data and then click CTRL+C to copy 
them). 
 Open a new Microsoft Excel file and paste all of the data in it (the data 
should form 6 columns identified as Sample, Chromosome, Start, End, 
Num_Probes, and Segment_Mean respectively). 
  Locate the control (benign nevi) sample names, which are listed in the 
first column (Sample). 
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 For each control (benign nevi) sample, there will more than a hundred of 
rows (starting from chromosome 1 to chromosome X as shown in the 
second column (Chromosome)).  
 Deleted all of the rows for all of the control samples.  
 Make sure to leave only the tumor (melanoma) samples in the Excel file 
without any space or empty rows between them.  
 Make sure not to delete any row that belongs to the tumor (melanoma) 
samples,where that can cause an error when running GISTIC. 
 Save the file as a text file. To do so, in Excel, click on File, then Save 
As, then name the file as '' cbsResult.seg ", then click on Save as type,  
then locate and select the type "Text(Tab delimited)", then click Save. 
7.  For the markers file parameter,   click the Upload File button and load 
the markersfile file (step 8 below explains the preparation of markersfile 
for GISTIC). 
8. How to prepare the " markersfile ":  
       This is a text file that identifies the marker names and positions in the 
original dataset before segmentation. It should contain three columns 
identified as: Marker, Chromosome, and physical position. The data in 
these three columns can be  taken from the CN 
"snp6_sample_data.pip3avg.log_mdQUAD" file (see the two important 
output files of the CopyNumberInferencePipelin above). To create the 
markersfile: 
 Open the snp6_sample_data.pip3avg.log_mdQUAD file. Note that this is 
a very large text file, so a large file text editor is needed to edit this file 
(EmEditor software was used to deal with this file).  
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 Copy only the first three columns (Marker, Chromosome, and Physical 
position). 
 Open a Microsoft Excel file and paste the copied three columns in it. 
  Make sure to copy all of the data in the three columns without missing 
any number (especially in the physical position column), where that can 
cause an error when running GISTIC.  
 Save the file as a text file. To do so, in Excel, click on File, then Save 
As, then name the file as '' markersfile", then click on Save as type,  then 
locate and select the type "Text(Tab delimited)", then click Save. 
9. The array list file and cnv file parameters, these are optional parameters 
and they can be ignored.  
10. For gene gistic parameter, Yes was selected (the default). This means the 
gene GISTIC algorithm should be used to calculate the significance of 
deletions at a gene level instead of a marker level. 
11. The amplification and deletion thresholds, these are thresholds that 
indicate the minimal copy-number variation sufficient to contribute to 
significance calculations. These parameters are used as cutoffs  to 
exclude the noise from the analysis, where the copy number events that 
are not really significant (with low log2 ratios) are not considered in the 
analysis. The default is to use 0.1 for both the amplification and deletion, 
where log2 ratios of the amplification copy number events above 0.1 
will contribute to the significant calculation ( log2 ratio above 0.1 of a 
certain genomic locus indicates that the locus has more than the normal 
copy number, which is 2. For example, the log2 ratio of a locus with 
three copy numbers = log2(3/2) = 0.58 > 0.1). Similarly, log2 ratios for 
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deletion copy number events below -0.1 will contribute to the significant 
calculation (log2 ratio below -0.1 of a certain genomic locus indicates 
that the locus has less than the normal copy number, which is 2. For 
example, the log2 ratio of a locus with 1 copy number = log2(1/2)= -1< -
0.1). Here, 0.1 was used for the amplification threshold and 0.3 was used 
for the deletion threshold (in our data, the deletions seem to be noisy, so 
0.3 was used to exclude the bulk of the noise and just consider the 
significant deletions that have log2 ratios below -0.3). Using these low- 
level cutoffs (0.1 and 0.3) allow of finding significant variation of all 
types; both broad low-level alterations and focal high level alterations. 
12. The join segment size parameter, this parameter indicates the smallest 
number of markers to allow in segments from the segmented data. 
Segments that contain a number of markers less than or equal to this 
number are joined to the neighboring segment that is closest in copy 
number. When the default threshold (4) was used, the amplification 
peaks looked good, but the deletion peaks looked so noisy. Therefore, 
looking in literature and at studies that used GISTIC, I noticed that some 
studies have set the parameter to 10, which means segments that contain 
a number of markers less than or equal to 10 are joined to the 
neighboring segment that is closest in copy number. So two GISTIC 
runs were performed, one with the parameter set to 4, and just the 
amplification results were considered, and the other run was done with 
the parameter set to 10, and only the deletion results were considered.  
13. The qv thresh parameter, this is a significance threshold for q-values. 
The q-values are obtained by correcting the resulting p-values for 
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multiple-hypothesis testing using Benjamini-Hochberg false discovery 
rate method [35]. These q-values represent an upper bound on the 
expected fraction of false positives in the resulting list. 0.25 (default) 
was used and regions with q-values below 0.25 are considered 
significant and are reported. 
14. The remove X parameter, which  indicates whether to remove data from 
the X-chromosome before analysis. The default (Yes) was used. 
15. The cap val parameter, which  indicates the minimum and maximum cap 
values on the analyzed data. The GISTIC runs were performed with cap 
values(in log2 ratio) of -2 and 2, where any values above 2 (8 copies) 
were replaced by 2 and values below -2 (0.5 copies) were replaced with -
2. These cap values were used to limit problems of hyper-segmentation 
that occur particularly in regions with extreme values due different 
attenuation curves of adjacent probes. 
16. The confidence level parameter, which  indicates the confidence level 
used to calculate the region containing a driver. 0.99 was used.  
17. The run broad analysis parameter, which indicates whether an additional 
broad-level analysis should be performed. The default (No) was used.  
18. The broad length cutoff parameter, which is used to distinguish broad 
form focal events, given in units of fraction of chromosome arm. 0.98 
(the default) was used, which means that copy number events spanning 
more than 98% of a chromosome arm are replaced with more narrowed 
peak. Yet, these narrowed peak still represent the broad copy number 
event when looking at the size of the genomic region. 
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19. The max sample segs parameter. This parameter sets the maximum 
number of segments allowed for a sample in the input data. Samples 
with more segments than this threshold are excluded from the analysis. 
The default (2500) was used in this analysis.  
20. The arm peel parameter, which indicates whether to perform arm level 
peel off or not. This helps separate peaks to clean up noise. The noise 
could be as a results of some samples showing disconnected (choppy) 
amplifications or deletions, which (in fact) seem to be  individual 
significant regions for different parts of  the same chromosomal 
alteration, this can cause GISTIC to report them as individual significant 
peaks, which causes the noise. This parameter was used (YES) to avoid 
these false peaks.  
21. After adjusting all of the parameters, click run to start the analysis. 
 
GISTIC sends the analysis job to the GenePattern server and displays the Job Status 
page. The running time depends on the number of samples being analyze (it can take 
days to run the analysis). 
 
Once the job is completed, GenePattern will display the results page, where many 
different output files will be shown. The important output files are: 
1. cbsResult.seg.all_lesions.conf_99. This is the all lesions file, which 
summarizes the results from the GISTIC run. It contains data about the 
significant regions of amplification and deletion as well as which 
samples are amplified or deleted in each of these regions. The identified 
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regions are listed down the first column, and the samples are listed 
across the first row, starting in column 10.  
2. cbsResult.seg.amp_genes.conf_99 file. This is a table of amplification 
peaks, followed by the genes contained in them, organized in  "ragged 
columns." The amp genes file contains one column for each 
amplification peak identified in the GISTIC analysis. The first four rows 
are: cytoband , q-value, residual q-value, and wide peak boundaries. The 
remaining rows list the genes contained in each wide peak. For peaks 
that contain no genes, the nearest gene is listed in brackets.  
3.  cbsResult.seg.del_genes.conf_99. Similar to the 
cbsResult.seg.amp_genes.conf_99 file, but this is for the deletion peaks. 
4. cbsResult.seg.amp_qplot. This is the Amplification GISTIC plot (in both 
PDF and PNG format) shows the G-scores (top) and q-values (bottom) 
with respect to amplifications for all markers over the entire region 
analyzed. 
5. cbsResult.seg.del_qplot. Similar to the cbsResult.seg.amp_qplot, but 
with respect to deletions for all markers over the entire region analyzed. 
6. cbsResult.seg.raw_copy_number. This is the segmented copy number 
file (both PDF and PNG) . It is a heat map image of the segmented copy 












III. RESULTS AND DISCUSSION: 
 
 
 Specimen collection and preparation: 
To Compare between the genetic-makeup of melanoma tumors and  benign 
melanocytic nevi, total of sixty-three melanocytic biopsy specimens (42 melanomas + 
21 benign melanocytic nevi) were identified in the archives of the Dermatopathology 
Lab of Central States (Dayton, OH).  These specimens (Table 1) were preserved in 
FFPE and stored at room temperature.  Specimens represent biopsies from a variety of 
locations on the skin.  All were found to be large enough to take a sufficient number 
of slides for the DNA extraction. 
  
Table 1: Details of specimens used in this study.  





Sex Location Clark's 
level 
Type 
1 M07 77 2008 Male Right Arm IV SUPERFICIAL SPREADING 
TYPE 
2 T10 - 2005 Male - - MALIGNANT MELANOMA 
3 T12 80 2005 Male Forehead IV DESMOPLASTIC TYPE 
4 T15 75 2005 Female Upper Back IV/V SUPERFICIAL SPREADING 
TYPE 
5 T17 - 2006 Male - - MALIGNANT MELANOMA 
6 M18 40 2007 Male Back IV MALIGNANT MELANOMA 
7 T19 60 2007 Female Left Leg IV NODULAR SPITZOID TYPE 
8 T20 - 2007 Female Elbow IV SUPERFICIAL SPREADING 
TYPE 
9 T23 81 2008 Male Left 
Auricular 
IV SUPERFICIAL SPREADING 
TYPE 




11 M28 60 2007 Female Left Leg IV NODULAR SPITZOID TYPE 
12 M30 - 2011 Male - - MALIGNANT MELANOMA 
13 M31 63 2008 Female Right 
Forearm 
IV SUPERFICIAL SPREADING 
TYPE 
14 M33 76 2008 Female Right Cheek IV SUPERFICIAL SPREADING 
TYPE 
15 M50 57 2010 Male Left Arm IV SUPERFICIAL SPREADING 
TYPE 
16 M54 45 2012 Female Left Back IV ULCERATED NODULAR 
MALIGNANT MELANOMA 
17 M56 60 2012 Male Left Shin IV SPITZOID TYPE 
18 M58 66 2011 Male Right Cheek  POORLY-DIFFERENTIATED 
CARCINOMA !!! 
19 M59 77 2011 Male Right Elbow IV INVASIVE MALIGNANT 
MELANOMA 
20 M64 27 2011 Female Right Neck IV POSTERIOR INVASIVE 
POLYPOID MALIGNANT 
MELANOMA 
21 M74 69 2010 Male Left Temple IV SUPERFICIAL SPREADING 
TYPE 
22 M75 74 2010 Male Left Neck IV SUPERFICIAL SPREADING 
TYPE 
23 M76 67 2010 Female Right Back IV Malignant Melanoma with 
verticle Growth 
24 M77 53 2010 Male Right Arm IV NODULAR MALIGNANT 
MELANOMA 
25 M84 - - Female - - MALIGNANT MELANOMA 
26 M86 54 2009 Female Anterior 
Thigh 
IV SUPERFICIAL SPREADING 
TYPE 
27 M98 72 2005 Male Right 
Shoulder 
III SUPERFICIAL SPREADING 
TYPE 
28 M107 80 2005 Male Forehead IV DESMOPLASTIC TYPE 
29 M111 48 2005 Female Right 
Forearm 
V NODULAR VARIANT 
30 M113 40 2007 Male Back IV Malignant melanoma 
31 M116 74 2007 Female Right Arm II SUPERFICIAL SPREADING 
TYPE 
32 M130 63 2001 Male Back IV SUPERFICIAL SPREADING 
TYPE 
33 M131 45 2001 Female Left Arm III SUPERFICIAL SPREADING 
TYPE 
34 M132 75 2001 Male Right Chest III-IV DESMOPLASTIC TYPE 
35 M136 40 2001 Female Upper Back III-IV NODULAR TYPE 
36 M137 85 2001 Female Right Cheek IV/V Malignant melanoma 
37 M139 87 2001 Male Right Cheek V CONSISTENT WITH THE 
LENTIGO MALIGNA 
MELANOMA SUBTYPE 
38 M147 90 2002 Male Left Back IV SUPERFICIAL SPREADING 
TYPE 
39 M148 55 2002 Female Middle Back II/III SUPERFICIAL SPREADING 
TYPE 
40 M173 28 2008 Female Left 
Shoulder 
III INVASIVE SPITZOID 
MALIGNANT MELANOMA 
41 M174 42 2008 Male Right 
Pretibial 




42 M191 75 2001 Male Left Back IV MELANOMA WITH 
REGRESSION 
43 NT06 34 2010 Male Right Arm - DERMAL NEVUS 
44 NT07 44 2010 Female Right 
Buttock 
- DERMAL NEVUS 
45 NT12 - - Male - - DERMAL NEVUS 
46 B15 19 2010 Female Left Back - DERMAL NEVUS 
47 B27 39 2011 Male Left Neck - DERMAL NEVUS 
48 B29 35 2011 Male Left Flank - DERMAL NEVUS 
49 B30 34 2011 Female Right Neck - DERMAL NEVUS 
50 B31 44 2011 Male Right Groin - DERMAL NEVUS 
51 B47 27 2011 Female Right Back - DERMAL NEVUS 
52 B51 62 2011 Female Right 
Eyebrow 
- DERMAL NEVUS 
53 B52 48 2011 Female Left Neck - DERMAL NEVUS 
54 B53_3 75 2011 Female Left 
Shoulder 
- DERMAL NEVUS 
55 B254 34 2007 Female Left Deltoid - DERMAL NEVUS 
56 B267 33 2013 Female Right Back - DERMAL NEVUS 
57 B272 38 2013 Female - - DERMAL NEVUS 
58 B279 52 2013 Female Right Back - DERMAL NEVUS 
59 B282 41 2013 Female Right Neck - DERMAL NEVUS 
60 B283 14 2013 Female Right 
Shoulder 
- DERMAL NEVUS 
61 B285 16 2013 Female - - DERMAL NEVUS 
62 B286 21 2013 Male Right Back - DERMAL NEVUS 
63 B287 60 2013 Female Right Neck - DERMAL NEVUS 
 
 
 The first slide and the last slide taken from each specimen were examined by staining 
with hemotoxylin and eosin (H&E) to verify the presence of cellular material in all 
sections (Figure 3). This is particularly important for the test sensitivity, where 
melanocytes should represent the majority of the entire tissue (> 60%) used for DNA 
extraction in order to avoid false-negative aCGH results [49]. Therefore, some of the 
melanoma samples' sections underwent microdissection to remove part of tissues that 














Figure 3: H&E staining for sections taken from melanoma sample. A) The first section taken 
from the sample showing melanoma cells (purple). B) The last section taken from the same 
sample showing that melanoma cells still present. C) The H&E staining showing atypical, 
pleomorphic cells of malignant melanoma. 
 
 
Improving the quality of DNA extracted from FFPE specimens: 
FFPE tissues represent a great wealth of human biospecimens that exists in the 
archives of many hospitals, tissue banks, and pathology laboratories. They are some 
of the most readily available biomaterials for researchers, due in part to their long 
shelf life and accreditation requirements for their storage. Despite the availability of 
archived specimens, the process of fixation complicates the use of nucleic acids from 
these tissue blocks [50]. Formalin treatment cross-links biological molecules such as 
DNA and proteins [51]. Additionally, longer nucleic acids like DNA and RNA, in 
particular, are fragmented in the preservation process, leading to poor performance in 
downstream analyses [52, 53].  Array CGH performs best with long, intact 
chromosomes.    This is one of the fundamental challenges of FFPE tissues.  During 
aCGH, genomic DNA is first digested with restriction enzymes and then these 




region between restriction sites is broken in our input, that region will not be 
represented in the material hybridized to the array. To optimize utility of nucleic acids 
from FFPE specimens for aCGH, we must reverse these cross links and avoid further 
degradation during the DNA or RNA extraction process. Therefore, we sought to 
improve the quality of the DNA by comparing DNA extracted from the same 
specimens by three different methods, phenol- chloroform-isoamyl alcohol, Qiagen 
columns, or adaptive focused acoustics (AFA), with consideration of  metrics of 
quantity and quality for each method.   
Twenty-seven benign melanocytic biopsy specimens were identified in the archives of 
the Dermatopathology Lab of Central States (Dayton, OH) and used in this quest 
(Table 2).  









1 30 F 8 Biopsy, nose, left side dermal nevus 
2 25 M 8 Biopsy, scalp, right post dermal nevus 
3 16 M 8 Biopsy, abdomen left dermal nevus 
4 35 F 8 Biopsy, back, left center dermal nevus 
5 38 M 8 Biopsy, scalp dermal nevus 
6 21 M 8 Biopsy, back right middle dermal nevus 
7 26 M 8 Biopsy, abdomen dermal nevus 
8 32 F 8 Biopsy, cheek, right dermal nevus 
9 31 M 8 Biopsy, axilla, right dermal nevus 
10 69 F 8 Biopsy, back, right upper dermal nevus 
11 40 F 8 Biopsy, axillary area. Anterior nevus lipomatosus 
superficialis 
12 44 F 8 Biopsy, calf, left post dermal nevus 
13 22 F 8 Biopsy, chest, left lateral neurotized dermal nevus 
14 56 M 8 Biopsy, cheek, left intradermal melanocytic nevus 
15 47 F 8 Biopsy, axilla, left dermal nevus 
16 35 F 8 Biopsy, chest dermal nevus 
17 29 F 8 Biopsy, back,midline lower neurotized dermal nevus 
18 34 F 8 Biopsy, deltoid left anterior dermal nevus 
19 44 F 8 Biopsy, lip,left upper dermal nevus 
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20 75 F 8 Biopsy, knee, left medial dermal nevus 
21 36 M 8 Biopsy, axilla right dermal nevus 
22 60 F 11 Biopsy, back dermal nevus 
23 16 F 11 Biopsy, back, left upper dermal nevus 
24 41 F 11 Biopsy, forehead,right neurotized dermal nevus 
25 16 F 11 Biopsy, back, inferior lower dermal nevus 
26 35 M 11 Excision, malar, left dermal nevus 
27 74 F 11 Biopsy, back, left upper dermal nevus 
Average: 38.04  8.67  
 
 After extracting DNA from the same 27 samples using phenol- chloroform-isoamyl 
alcohol, Qiagen columns, or adaptive focused acoustics (AFA), the DNA was 
separated by electrophoresis to determine the genomic DNA size range.  Four 




Figure 4: ) Genomic DNA size range of samples extracted by three different methods . Genomic 
DNA was extracted from four specimens (numbered 1-4) by three different methods,  Phenol 
chloroform isoamyl alcohol (“Phenol”), commercial column-based extraction kit (“Column”) and 
adaptive focused acoustics (“AFA”).  Total extracted DNA was separated by electrophoresis on 
1% agarose. 
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Samples with visible DNA fragments as large as 23,000 base pairs (bp) are considered 
eligible for further processes. Here, DNA extracted by AFA showed slightly higher 
size distributions, but these results were mostly equivocal, suggesting that any method 
worked about as well as the other. 
The quantity and quality of the extracted DNA was compared across all samples.  
Interestingly, there was a significant difference in the DNA yield per section between 
methods. This controlled for the number of slides used in each extraction as well as 
the elution volumes used for each method.  A variety of incubation times have been 
suggested in the literature for deparaffinization and proteinase K digestion [42, 54-
56]. Increasing the proteinase K digestion time from one hour to overnight or even 72 
hours has been shown to increase the amount of retrieved DNA in some studies [42, 
54];  therefore, in this study a  prolonged proteinase K digestion time was afforded to 
both the phenol-chloroform and column methods to compare best performance against 
the newer AFA method.  Here there was a clear difference between the column-based 
method and the other two methods.  The commonly used column-based kit (Qiagen) 
retrieved approximately twice as much DNA per section as phenol-chloroform or 
AFA. Table 3 shows the quantification of recovered DNA by both a fluorometric 
method (Qubit) and a spectrophotometric method (Nanodrop).  
Table 3: Summary of the QC metrics for the methods comparisons. 
Quality Metrics Phenol Column AFA 
DNA (ng)/section (Qubit) 106.2  33.1 264.3  35.4 134.6  18.1 
DNA (ng)/section (Nanodrop)         702.1 200.2 716.0   116.1 453.8  53.9 
A260/A280 1.94   0.02 2.04  0.03 1.90  0.02 
A260/A230 1.71   0.18 1.71  0.12 1.75  0.43 
Max. amplicon (bp) 346.7   24.1 347.4  21.4 401.9  10.2 





Importantly, purity of the DNA is critical for most applications.  Inhibitors of PCR 
can be carried over from the purification process and become apparent first by 




 ratios.  Therefore, the purity of the extracted DNA 
was compared by spectrophotometry to measure absorbance at 260 and 230 





 ratio of approximately 1.7, which is sufficient for most applications 
(Table 3).  
 
  In order to measure the performance of the DNA in downstream PCR, RAPD-PCR 
was performed for each sample across all three extraction methods. The ability of the 
DNA to be amplified by PCR is a measure of its purity, as common contaminants 
(such as alcohols, xylene, and salts) often inhibit the PCR reaction (the utilization of 
RAPD-PCR as a quality control step is discussed further in the "RAPD-PCR, a 
predictor for aCGH success of FFPE samples ) section. Here, DNA produced by AFA 
showed amplicons of greater length than DNA extracted by other means (Table 3). 
Furthermore, more products of a larger size were able to be amplified from DNA 







Figure 5: ) RAPD-PCR profile of 4 samples extracted by three different methods. Extracted DNA 
was used for randomly amplified polymorphic DNA (RAPD) PCR to produce a variety of 
amplicons.  The same four samples (1-4) isolated by three different methods were compared side-
by-side.  +, positive control Jurkat genomic DNA. More products of a larger size were obtained 
from DNA extracted by AFA.  
 
Additionally, the PCR failure was calculated to observe the performance of the DNA 
extracted from each method in the RAPD-PCR. We defined PCR failure as a RAPD-
PCR resulting in amplicons less than 300 bp in length; we do not proceed to use these 
samples as this predicts poor performance in downstream PCR [43]. The rate of these 
failures was over 25% by phenol-chloroform and over 22% by columns.  However, 
only one of 27 samples (3.7%) failed by AFA (Table 3).  An alternative explanation 
for failure to produce larger amplicons is that each method varies in its ability to 
extract intact DNA molecules of sufficient length.  This is suggested by a greater 
proportion of gDNA below 2,000 bp in Figure 3 for phenol-chloroform and column 
methods.  One possibility is that the reduced processing times involved in AFA 
reduces the likelihood that any longer DNA molecules present in the FFPE sample 
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when determining what method to use, these gains must be weighed against the 
increased purity, greater amenability to PCR, lower PCR failure rates, and recovery of 
larger chromosomal fragments when DNA is obtained by AFA.  These findings 
support AFA as an improvement over previous DNA extraction methods for FFPE 
tissues [57].  For aCGH analysis, none of the samples prepared by phenol-chloroform 
performed well in the PCR amplification step of the SNP6 protocol.  Even when 
sufficient amplicon length was observed, the total DNA yield was insufficient to 
move forward with hybridization to arrays. Therefore, only DNA extracted by 
column-based extraction methods (Qiagen columns, or adaptive focused acoustics 
(AFA)) was used in the copy number analysis. 
 
 RAPD-PCR, A predictor for aCGH success of FFPE samples. 
Most applications using gDNA from clinical specimens will begin with PCR 
amplification. SNP genotyping, copy number analysis, comparative genomic 
hybridization, and other methods all depend on the “amplifyability” of the gDNA.  
For array CGH in particular, longer amplicons leads directly to greater fragment 
representation in the final analysis. Randomly Amplified Polymorphic DNA (RAPD) 
PCR is useful for predicting the suitability of a DNA sample for downstream PCR 
[43].  While RAPD-PCR does not reliably produce the same specific bands on a gel, 
we have found RAPD-PCR to be a rapid method to screen many amplicons using a 
single PCR reaction, and that these results are generally a good measure of 
performance in downstream applications (specifically aCGH). Therefore, we have 
included the RAPD-PCR as a quality control step, by which we can screen the DNA 
ability to be amplified, and identify which samples to be ideal for SNP 6.0 work. 
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The size range of RAPD products reflect the degree of DNA degradation, where 
samples that produce a RAPD profile with more than 300 bp fragments are considered 
eligible to be used in aCGH analysis. On the other hand, samples that produce a 
RAPD PCR profile with less than 300 bp fragments are considered low-quality DNA 
and not used for aCGH analysis (Figure 6).  
  
 
Figure 6: ) RAPD-PCR profiles for 12 different samples. +, positive control Jurkat genomic DNA. 
Samples # 5, 8, and 12 showed RAPD PCR  product of less than 300 bp fragments, which 
indicates the low quality of the DNA from these samples. The other samples showed RAPD PCR 




Using the RAPD-PCR as a prescreening technique allows as to avoid using samples 
with low-quality DNA in the aCGH analysis, thus increasing the reliability and 









8 7 6 4 5 3 2 1
0 
11 9 12 + 10 
56 
 
Processing the qualified DNA through SNP 6.0 protocol. 
Array-based genotyping platforms, such as the Affymetrix SNP6.0 microarrays have 
been validated to be a reliable method for obtaining high resolution copy number 
information [53, 58, 59]. Unlike other cytogenetic techniques such as FISH, these 
high-density single-nucleotide polymorphism (SNP) arrays allow for detailed and 
genome-wide identification of copy-number alterations in one experiment, which 
make it a powerful discovery tool. The principle of these arrays depends on the 
hybridization of fragmented single-stranded DNA to arrays containing hundreds of 
thousands of unique nucleotide probe sequences; each probe is designed to bind to a 
target DNA subsequence. The high-density SNP6.0 microarrays contain over 940,000 
probes for interrogating copy number variations in the entire genome [60].  
In order to analyze copy number variation of DNA samples, the DNA needs to be 
processed through different enzymatic reactions and prepared for hybridization to the 
microarrays. The DNA first is digested by restriction enzymes (Sty I and Nsp I) to 
produce different size DNA fragments. This step is highly sensitive to the level of the 
DNA degradation in the starting material, where the higher the DNA is degraded, the 
lower the number of restriction sites still present and therefore the less-efficient is the 
PCR amplification step [61]. The digested DNA fragments are then ligated to 
adaptors that recognize the sticky ends of the restriction sites. These adaptors-ligated 
DNA fragments are then amplified to reduce the genome complexity. The PCR 
conditions were optimized to amplify DNA fragments in the size range of 200-1100 
bp and yield a final PCR product concentration (for a typical sample) 4.0 to 6.5 µg/µl. 
However, because the DNA from FFPE samples is partially degraded, this causes 
less-efficient amplification and lower PCR yield. Samples that yielded less than the 
desired PCR product concentration were excluded from moving forward with 
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hybridization to the arrays (such as in case of samples extracted by the phenol-
chloroform method). Therefore, the PCR amplification step was modified to optimize 
the range of the product size and the yield concentration. The number of PCR 
reactions was doubled from the suggested three for Sty1 and four for Nsp1 to six for 
Sty1 and eight for Nsp1.  It is important to note that the number of reactions was 
increased; the number of cycles in each reaction remained the same. Also, the input 
DNA was increased from 250 ng to 500 ng. These modifications improved the 
amplification performance and helped yielding an optimal PCR product concentration 




Figure 7: ) Example of SNP6.0 PCR product of 4 different samples run on 2% agarose gel. +, 
positive control Jurkat genomic DNA. -, negative control, a mock reaction with no template DNA. 
The same 4 samples were digested first with Sty I and Nsp I restriction enzymes, and then ligated 
to adaptors. The adaptors-ligated fragments were PCR-amplified.  All samples showed average 
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The PCR product of Sty and Nsp will be combined and then purified. After 
purification, the DNA undergoes an important step, which is fragmentation. DNase I 
enzyme is used to unspecifically fragments the PCR product into small fragments. In 
order for these fragments to successfully hybridized to the SNP6.0 microarrays, they 
must be around 200 bp (Figure 8).  
 
 
Figure 8: ) Examples of Enzymatic fragmentation performances run on 4% agarose gel. The 
fragmentation resulted in all samples showing product of around 200 bp fragments.  
 
 
The fragmented DNA is then labeled with a DNA labeling reagent. After that, the 
fragmented and labeled DNA will be prepared for the hybridization step, where the 
DNA is denatured  on a thermal cycler. After denaturation, each sample will be 
loaded onto the Genome-Wide Human SNP array 6.0 (one sample per array) and 








As a QC step, a program called Affymetrix Power Tools (APT) can be used to 
evaluate the microarrays and determine which restriction-PCR products had 
successfully hybridized to the microarrays. The APT program analyzes the probe sets 
and then assigns a call rate to each of the restriction fragment length depending on 
how successfully they were hybridized to the microarrays. A contrast QC of at least 
0.4 indicates a successful hybridization of DNA fragments to the arrays. The expected 
restriction fragments are binned by size and graphed versus their abundance on 
hybridized arrays. Since the DNA in the starting material is partially degraded, we do 
not expect the hybridization efficiency to be ideal (200bp-1400bp). Yet, we were able 
to get hybridization efficiency of DNA CQC > 0.5 for DNA fragments 500-600 bp 
long (Figure 9).  The representation of restriction fragments on the microarrays 










Figure 9: ) APT analysis of  Nsp1 (blue) and Sty1 (red)  . Contrast QC, the ability to resolve 
between alleles on the arrays, was calculated for each probe and plotted against the length of the 
restriction fragment containing that target. Restriction for these arrays is performed with the 
enzyme Sty1 (Red) or Nsp1 (Blue). Fragment length was divided into 100 bp bins (x-axis). 
Median CQC is shown in the bar graph (left y-axis). Distribution of the data is shown by the 
superimposed box plot (right y-axis).The two graphs show that the probes in the arrays have 
bound to the DNA fragments at different sizes (200bp – 600bp).   
 
   
 
Validating the recurrent copy number changes in melanoma. 
Upon hybridizing all of the melanoma and benign samples, and having the data ready 
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alterations that have been reported in literature. Different melanoma studies have 
shown some genes that are frequently amplified or deleted in melanoma samples. By 
applying the Integrative Genomic Viewer (IGV) on the segmented copy number data 
generated by the CopyNumberInferencePipeline, we can search through the 
segmented data and inspect the known melanoma genes. IGV shows the copy number 
segmented data as a heatmap ranging between log2 ratios -1.5 to 1.5, where genomic 
regions with blue color have relatively lower copy number than the normal copy 
number (2). On the other hand, genomic regions with red color indicate gain in the 




Figure 10: ) IGV copy number scale. Blue color represent deletion, red color represent 
amplification, and white color represent normal copy number. The different shades of the color 
represent magnitudes as log2 signal intensity ratios. Log2 ratio of 1.5 represents high 
amplification (5.6 copies); and log2 ratio of -1.5 represent high deletion (0.7 copies).  
 
The validation began by looking at a comprehensive overview of the segmented data 
of the entire genome. We found that most of the melanoma samples exhibit intense 
copy number changes. In contrast, benign nevi samples show normal copy number 
throughout their entire genome (Figure 11). This difference in copy number alteration 
pattern between melanoma and benign nevi has been shown to be a distinguishing 
characteristic of melanoma and has been exploited to discriminate between melanoma 
and benign nevi [22, 25, 62-64]. 
 




Figure 11: ) A comprehensive overview of the segmented copy number data of the analyzed 
melanoma and benign nevi genome. The horizontal axis represents the genome from 
Chromosome 1 to Y. The vertical axis represents the samples. Blue color indicates a deletion in 
that region of the genome and red color indicates an amplification. Samples above the black 
horizontal line are benign nevi sample, and samples below the line are melanoma samples. 
 
We then sought to inspect the known copy number changes associated with 
melanoma. Several studies have reported frequent amplification and deletion of some 
genes in melanoma, but not in benign nevi specimens. Among the highly amplified 
genes associated with melanoma tumorigenesis are the melanoma metastasis gene 
NEDD9 [34], the proto-oncogene transcription factor MYC [65], and also AKT3 [66, 
67]. We found that most of the melanoma samples show different level of 
amplification of these  genes in comparison with the benign nevi samples (Figure 12 






















Figure 12: ) Copy number change of  known amplified genes in melanoma.  The vertical axis 
represents the samples. Samples above the black horizontal line are melanoma sample, and 
samples below the line are benign nevi samples. The gene name is indicated below the heatmap in 
each figure. The CNV summary on the left above the sample names indicates the overall copy 
number change in the selected gene. A) Amplification of NEDD9. B) Amplification of MYC. C) 
Amplification of AKT3.  
 
 
Similarly, several studies have reported a frequent deletion of some genes in 
melanoma samples. Among the highly deleted genes in melanoma are the Wnt1 
Inducible Signaling Pathway protein 3 (WISP3) [68], the tumor suppressor and the 
melanoma susceptibility gene CDKN2A [69, 70], and the tumor suppressor gene 
PTEN [71]. Examining these genes in our analysis showed that most of the melanoma 
samples carry deletions within these genes, while benign nevi samples show no 



















Figure 13: ) Copy number change of  known deleted genes in melanoma.  The vertical axis 
represents the samples. Samples above the black horizontal line are melanoma sample, and 
samples below the line are benign nevi samples. The gene name is indicated below the heatmap in 
each figure. The CNV summary on the left above the sample names indicates the overall copy 
number change in the selected gene. A) Deletion of WISP3. B) Deletion of CDKN2A. C) Deletion 
of PTEN. 
 
These initial data indicates regions of amplifications and deletions that are conserved 
within the samples. These results are consistent with the conserved amplification and 
deletions reported in literature, which indicate the reliability of our analysis. These 
'proof of principle' results lend confidence of any novel copy number changes that 
may arise from this study.  
 
 Genomic identification of significant targets in melanoma. 
Somatic copy number variations play a fundamental role in cancer development and 
progression [37, 72]. These genetic variations can contribute in activation or 
inactivation of cancer genes, such as oncogenes and tumor suppressor genes [73]. 
Knowing and understanding of such genetic alterations have dramatically advanced 
cancer diagnosis and therapeutics [74-76]. However, copy number changes can affect 
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broad genomic regions spanning a large number of genes. Nevertheless, one or few of 
these genes (drivers) are more likely to be responsible for the tumorigenesis [35]. In 
melanoma, copy number studies have reported a variety of different recurrent genetic 
alterations affecting large chromosomal segments, without (or with few) target genes 
identified. Therefore, there still a great demand to identify novel melanoma drivers 
targeted by such somatic copy number changes, which will help improve the 
melanoma diagnosis, assessing prognosis, and developing targeted therapies. 
The task of revealing new cancer genes being targeted by somatic copy number 
changes is not simple. The difficulty lies in distinguishing the driver alterations 
(cancer driver genes) that contribute to tumorigenesis from the random somatic 
passengers [36, 77]. The great advancement in the technology of microarrays helps 
yielding precise and detailed DNA copy number profiles corresponding to gains or 
losses of DNA segments in tumor samples. These DNA copy number profiles are 
useful in looking at specific genomic region of interest and examining them (see 
"Validating the recurrent copy number changes in melanoma" above). Nonetheless, 
finding driver events in these noisy, detailed, row copy number data acquired from the 










Figure 14: Row-segmented copy number data obtained from the SNP6.0 microarray analysis of 
42 melanoma samples inferred from log2 ratios by CopyNumberInferencePipeline. Chromosome 
positions indicated along the x axis. Samples are arranged horizontally from top to bottom. Red: 
regions of gain; blue: regions of loss.  
 
However, an effective way to discover key genes (drivers) that play casual roles in 
cancer development and progression is to study a large number of tumor samples and 
detect genomic regions that undergo frequent alterations across the samples. This is 
based on the fact that genomic regions that contain driver genes should be affected 




Figure 15: A driver mutation should occur in multiple tumors more often than would be expected 
by chance. 
 
Therefore, we applied a rigorous statistical method called Genomic Identification of 
Significant Targets In Cancer (GISTIC) to the row copy number data obtained from 
our microarray analysis of 42 melanoma samples.  GISTIC detects regions of 
aberration that are more likely to promote tumorigenesis. It does so by  identifying  
genomic regions that are altered more often than would be expected by chance, with 
priority to high amplitude aberrations (for example, high level copy number 
amplifications or homozygous deletions) [35, 36].  
GISTIC analysis of 42 melanoma samples revealed statistically significant large 
regions and focal peaks of chromosome gain and loss. 8 regions of significant copy 
number gain and 32 regions of significant copy number loss. Broad regions of 
amplifications were shown on 1q, 6p, and 8q; focal amplification peaks were 








Figure 16: Statistically significant genomic amplifications identified by GISTIC analysis. 
Chromosome positions are indicated along the x axis with centromere positions indicated by 
dotted lines. The statistical significance of the aberration are displayed as false-discover rate q-
values on the right y axis (significant for values <0.25, represented as a horizontal green line). G-
score at the left y axis weights to the amplitude of aberrations and the frequency of it is 
occurrence across samples (see material and methods). Interesting or known genes are indicated 
at the top of the peaks. 
 
 
 Description of the regions of amplifications identified by GISTIC is in (Table 4). The 
importance of each peak in cancer pathogenesis and how they are correlated with 
































Table 4: Description of the statistically significant amplified regions Identified by 
GISTIC.  
Rank Genomic                     
Location 




Known in Cancer  Known in 
Melanoma 
1 21q22.1 chr21:39861045-39866904 2.22E-7 1 ERG - 
2 11q14.1 chr11:83358080-83366882 2.56E-7 1 DLG2  - 
3 10q11.21 chr10:43622934-43623811 5.92E-4 1 RET - 
4 6p24.3 chr6:1-22748031 1.17E-2 118 NEDD9, DEK, E2F3 6p, NEDD9, 
RREB1, DEK 
5 7p14.3 chr7:34477091-34483332 1.17E-2 1 - 7p 
6 1q31.2 chr1:114755790-249250621 1.30E-1 1206 AKT3,MDM4, ABL2 1q 
7 8q24.23 chr8:99387730-146364022 1.30E-1 284 MYC MYC 
8 7p12.3 chr7:46879412-46880294 1.30E-1 1 7p12 7p 
 Identified peaks are listed in the table based on their significant q-value. 
 
 
Discussions regarding the importance of each peak in cancer and  how they are 
correlated with previous findings in melanoma:-  
 
21q22.1:  
This region has not been shown to be amplified in melanoma before. Only one gene 
was reported in this region , which is ERG. ERG "Avian v-ets erythroblastosis virus 
E26 oncogen" is a proto-oncogene that belongs to the ETS transcription factor gene 
family that plays a role in embryonic development, cell proliferation, angiogenesis, 
and apoptosis [81, 82]. Overexpression of ERG has been found in different cancers 
including Ewing sarcoma, acute myeloid leukemia, and meningiomas [81]. Moreover, 
the oncogenic role of ERG is prominent in the TMPRSS2-ERG fusion gene in 
prostate cancer[83-87]. These recent findings have declared the role of this gene in 
cancer. In this study, a high focal amplification targeting the ERG gene on 
chromosome 21 was identified. This focal amplification strongly suggests that ERG 





This region has just one gene, which is DLG2. DLG2 "discs, large homolog2" is a 
member of membrane-associated guanylate kinases family that has important roles in 
tissue developments, cell-cell communications, cell polarity control, and cellular 
signal transductions [88]. A study found DLG2 was upregulated in renal oncocytoma, 
a benign tumor of the kidney, which explains it's potential role as an oncogene[89]. 
Interestingly, this chromosomal location"11q14.1" is located close to 
11q13"CCND1", an amplified region in melanoma that is used as a FISH target to 
distinguish between melanoma and benign nevi[7]. 
10q11.21: 
This peak represent a focal amplification of this region that spanned the RET gene. 
RET "Rearranged during transfection" is a proto-oncogene that encodes a 
transmembrane receptor tyrosine kinase [90-92]. RET has been shown to have an 
important role in human cancers [91, 92], and it's amplification and overexpression 
have been reported in different types of cancers such as thyroid cancer [93], lung 
cancer [94], breast cancer [90], and pancreatic cancer [95]. Furthermore, RET has 
been shown to be involved in activation of several important signaling pathways 
including PI3K, Ras/MAPK, Jun N-terminal kinase "JNK" and PLC-dependent 
pathways [92, 96].  
In melanoma, a study on human melanoma cell lines has showed a correlation 
between the expression of RET and melanomagenesis. Also, the study showed that 
inhibition of RET signaling suppressed all proliferation and invasion in melanoma 
[96]. Another study reported the involvement of RET in melanoma development in 
RET-mice and human melanoma cells [97]. These two studies besides the focal region 
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of amplification centered on the RET gene in our study indicate the potential 
importance of RET in melanoma. Therefore, our study suggest that RET could be one 
of the driver genes in melanoma tumorigenesis. 
6p24.3: 
Gain of 6p is a common chromosomal imbalance in several human cancers, which 
indicate the importance of genes involved in this region in cancer pathogenesis [98]. 
In melanoma, gain of 6p is one of the most common chromosomal abnormalities that 
was reported in several studies [5, 6, 24, 25, 34, 98, 99].  Identifying important genes 
in this large gain still a challenge. In melanoma, the minimal region of 6p gain has not 
been characterized [99]. In our study, this peak "6p24.3" represents a partial gain of 
6p (22.74 Mb). Interestingly, several important genes in melanoma were identified in 
this peak. NEDD9, one of the main melanoma metastasis genes [34], RREB1, one of 
the FISH assay targets that is used to distinguish between melanoma and benign 
nevi[7], and DEK, an oncogene that was reported to have a dual and selective roles in 
proliferation and apoptotic resistance in melanoma [99]. Another important gene in 
this region is E2F3 gene, an oncogene that has an important role in tumorigenesis in 
bladder cancer [100]. Therefore, against the large background of 6p gain that is 
common in melanoma, the partial gain of this part of chromosome 6p in our analysis 
(with known genes in melanoma located in this part) minimizes the broad gain of 6p  
to a smaller region that is highly associated with melanoma. 
1q31.2: 
This peak represents gain of the entire long arm of chromosome 1 (1q). Gain of the 
long arm of chromosome 1 represents a common genetic alteration in melanoma [5, 6, 
24, 25, 98]. A CGH study has shown that Patients with 1q and 6p gain had a lower 
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overall survival rate in comparison with patients without these gains, which implies 
that 1q and 6p gains could give a prognostic differences [101]. Several  important 
genes in cancer, and more specifically in melanoma, are located on this genomic 
region. This includes AKT3 [66, 67], MDM4 [102], and ABL2 [103]. Our study 
confirms that gain in chromosome 1q as one of the most genetic alterations in 
melanoma.  
8q24.23: 
Gain of 8q is another hallmark in melanoma that was reported in many different 
studies [4, 6, 24, 25, 104]. In our findings, the peak on chromosome 8 represent high 
amplification of a part of the long arm of chromosome 8, which is 8q24. A study has 
suggested that targeting this region "8q24" by FISH assays could be a useful 
prognostic marker in melanoma cancers[105]. Later, a recent study that sought to 
improve the sensitivity and specificity of FISH assay for discriminating melanoma 
from nevi  has confirmed  and included the 8q24 region as one of four FISH targets 
with high discriminatory power to differentiate between melanoma and benign 
nevi[7]. The most prominent gene in this region is MYC, a proto-oncogene that 
encodes a nuclear phosphoprotein transcription factor that plays a role in different 
cellular processes, such as proliferation, cell cycle progression, metabolism, 
differentiation and apoptosis[106]. MYC amplification has been shown in different 
cancers including prostate [107]and breast cancer [108]. In melanoma, it has been 
shown that melanomas with gain of 8q24 have elevated cytoplasmic and membranous 
expression of MYC in comparison with melanomas without gain of 8q24, where they 
had significantly decreased MYC expression. This elevated expression of MYC 
seems to play a role in the aggressive clinical behavior of melanomas [65]. This is 




7p12.3 & 7p14.3: 
Gain of the p arm of chromosome 7 is one of the most common copy number gains in 
melanoma [6, 24, 25, 109]. On the other hand, the q arm in melanoma is known with 
the activating point mutation of the BRAF oncogene [110]. Although the gain of 7p is 
common in melanoma, targets in this arm still undescribed [109]. Here, two focal 
amplifications were identified in our study, 7p12.3 and 7p14.3 regions. For the 7p12.3 
region, GISTIC has reported this region with no known genes, but only one gene 
(TNS3) was denoted in brackets, which indicates that it is the nearest known gene to 
that region. Despite what gene was found here, this chromosomal region has got the 
attention in cancer studies. Amplification of this region has been reported in different 
types of cancers including amplification of 7p12.3 in pancreatic cancer[111] and 
rectal cancer [112]. Also amplifications in the 7p12 band has been shown in acute 
lymphoblastic leukemia [113] and osteosarcomas [114]. The attention to this region is 
mainly because that the oncogene EGFR "Epidermal growth factor receptor" is 
located in this band [115]. EGFR is known to play a role in metastasis, cellular 
proliferation, invasion, and in cancer progression in general [116]. Gain of 7p12 band 
has been associated with gain of EGFR gene as in the squamous cell carcinoma of the 
lung [117] and gastric cancer [118]. In melanoma, a study that used two different 
cytogenetic approaches "FISH and aCGH" has found a frequent amplification of the 
region "7p12.3" among melanoma samples[68]. Other studies that focused on the 
expression level of EGFR on 7p12.3 in melanoma have shown a correlation between 
high expression of EGFR and gain in copy number of this region, which might 




The other region, 7p14.3, was reported with amplification of just one gene, 
AAA1(NPSR1-AS1). However, these findings do not exclude the possibility that 
other genes located at 7p14 can be influenced by this gain of this region. An example, 
the gene NPSR1, a G protein coupled receptor, which is located on 7p14.3. 




The importance of our results lies in showing a focal amplification of 7p12-p14 
region in chromosome 7p as a statically significant copy number gain, instead of 
showing a broad copy number change that encompasses the entire arm, which implies 




















Regarding the statistically significant deletions that were found by GISTIC, large 
regions of deletions were identified on 2q33, all of 9, 13q34, 15q26, 16p13, and 
22q13; focal deletion peaks were identified on 1q21.3, 1p32.3, 2p21, 3q13.31, 3p22.1, 
4p16.3, 5q35.1, 5q35.3, 5p15.33, 6q14.1, 6q26, 6p22.1, 8p23.2, 9p21.3, 10q23.2, 
10p15.3, 11q13.1, 11p15.4, 12q21.31, 13q13.3, 15q26.1, 16q23.3, 17q11.2, 18p11.31 




Figure 17: Statistically significant genomic deletions identified by GISTIC analysis. Chromosome 
positions are indicated along the x axis with centromere positions indicated by dotted lines. The 
statistical significance of the aberration are displayed as false-discover rate q-values on the right 
y axis (significant for values <0.25, represented as a horizontal green line). G-score at the left y 
axis weight to the amplitude of aberrations and the frequency of it is occurrence across samples 









Description of the regions of deletions identified by GISTIC is in (Table 5). The 
importance of each peak in cancer pathogenesis and how they are correlated with 




Table 5: Description of the statistically significant deleted regions Identified by GISTIC. 
Rank Genomic                     
Location 




Known in Cancer  Known in 
Melanoma 
1 8p23.2 chr8:1986591-6269441 1.5489E-
7 
3 CSMD1 8p 
2 4p16.3 chr4:1-1110173 1.74E-04 23  FGFRL1 - 
3 6q26 chr6:161767520-163770210 1.74E-04 4 PARK2, PACRG  6q 
4 11q13.1 chr11:63680046-63774300 1.74E-04 3 OTUB1 11q 
5 2p21 chr2:42180913-42397164 2.03E-04 1 EML4 - 
6 5q35.3 chr5:179219193-179388308 1.04E-03 6 SQSTM1 5q 
7 6p22.1 chr6:29427138-29498496 1.36E-03 1 6p22.1 - 
8 5p15.33 chr5:1-1054830 2.56E-03 18 SDHA, AHRR, NKD2  - 
9 16q23.3 chr16:82658729-83542835 3.40E-03 3 CDH13 16q 
10 17q11.2 chr17:29704122-29872630 7.98E-03 2 NF1 NF1 
11 12q24.31 chr12:124452696-125266431 1.18E-02 4  NCOR2 (SMRT) 12q24 
12 20q11.21 chr20:31830310-31946860 1.43E-02 1 BPIFB1 (LPLUNC1) - 
13 6q14.1 chr6:80412926-80513550 2.10E-02 1 SH3BGRL2 6q 
14 10q23.2 chr10:88278583-88520408 2.67E-02 2 WAPAL 10q 
15 5q35.1 chr5:169759991-169932228 2.77E-02 1 - 5q 
16 16p13.3 chr16:1-752680 2.80E-02 40 AXIN1, ARHGDIG 16p 
17 13q13.3 chr13:36341439-36742905 3.05E-02 1 DCLK1 13q12-34 
18 3q13.31 chr3:114054708-114463757 4.46E-02 3 ZBTB20 - 
19 10p15.3 chr10:1208827-1601334 5.09E-02 2 ADARB2   
20 3p22.1 chr3:42451413-42590432 5.27E-02 1 VIPR1 - 
21 1p32.3 chr1:54870183-55085182 5.81E-02 1 ACOT11 - 
22 11p15.4 chr11:3076258-3249828 5.81E-02 3 11p15.5 11p 
23 21q22.3 chr21:45878481-48129895 5.81E-02 50 21q22.3 21q22.3 
24 18p11.31 chr18:6929284-7231471 6.72E-02 1 LAMA1 - 
25 1q21.3 chr1:154596123-154898074 7.09E-02 1 KCNN3 - 
26 2p21 chr2:44460525-44590065 7.09E-02 3 PPM1B  
27 9p21.3 chr9:20651454-25679201 7.09E-02 34 CDKN2A, CDKN2B CDKN2A, 
CDKN2B 
28 22q13.32 chr22:41481652-51304566 7.09E-02 154 BIK, PRR5, PANX5 - 
29 2q33.2 chr2:200814810-206486163 1.10E-01 45 RAPH1,CASP8, ABI2 - 
30 13q34 chr13:109280035-115169878 1.47E-01 42 ING1, COL4A1, COL4A2 - 
31 15q26.1 chr15:91642272-93012556 1.51E-01 3 SLCO3A1 - 
32 Chr.9 chr9:1-141213431 1.91E-01 953 Chr.9 Chr.9 












Discussions regarding the importance of each peak in cancer and  how they are 





This region was reported by GISTIC with the lowest q value among all other 
deletions. Loss or decrease in copy number in chromosome 8p has been observed in 
melanoma[4, 24, 25] and other cancers such as prostate cancer[122] and breast 
cancer[123]. Despite the frequent deletion of this chromosomal arm in melanoma, the 
molecular drivers of the 8p loss remain uncharacterized. Here, our study shows a 
minimal region of deletion within chromosome 8p. This focal deletion of 8p23.2 
harbors the tumor suppressor gene CSMD1. Deletion of this minimal region with the 
tumor suppressor gene CSMD1 has been reported in many different cancers, 
including colorectal cancer [124], liver cancer [125], ovary cancer [126], and more 
common in  the head and neck squamous cell carcinoma (HNSCC) and correlates 
with poor prognosis [127, 128].  In melanoma, a recent study of Tang et al " the only 
study that have shown the effect of CSMD1 on melanoma cell, as they claimed" has 
reported that CSMD1 functions as a tumor suppressor gene in melanoma cells. They 
found that the level of CSMD1 mRNA and protein in melanoma cells was lower than 
in normal skin cancer. Also, they showed that CSMD1 expression decreased 
proliferation and migration, and increased apoptosis and G1 arrest in A375 melanoma 
cells in vitro. Furthermore, the survival rate of mice with tumors expression CSMD1 
was significantly higher than mice with tumors that did not express CSMD1. 
Moreover, the study showed that CSMD1 exhibits antitumor activity through 
activation of Smad pathway[129]. That study and our study provide CSMD1 as a 




Deletion of the short arm of chromosome 4 is common in several cancers including 
breast cancer [130], colon cancer [131], gastric cancer [132], and lung cancer[133]. 
However, deletion of this chromosomal arm does not seem to be noticed in 
melanoma. Yet, loss of the chromosome 4 has been reported in melanoma before [4]. 
In this study, a novel minimal deletion of the 4p16.3 telomeric region was identified. 
This region spanning 1.05 Mb included 26 genes, 6 of which are zinc finger genes. An 
interesting gene that is also mapped to this region is the atypical fibroblast growth 
factor receptor (FGFRL1). Deletion or LOH of the FGFRL1 has been investigated 
intensively in bladder cancer, where a recent study [134] has investigated the role of 
FGFRL1 as a candidate tumor suppressor in cancer. The reasons that were proposed 
to consider FGFRL1 as a candidate tumor suppressor were that FGFRL1 acts as a 
decoy receptor preventing activation of conventional FGFRs due to its lack of the 
intracellular tyrosine-kinase domain, also it interacts with the negative regulator of the 
MAPK signaling pathway SPRED1, and it is ability to promote cell adhesion by 
promoting cell adhesion and could therefore prevent tumor development and 
spreading by enhancing cell-cell adhesion and inhibiting invasion and metastasis 
[134]. Moreover, FGFRL1 has been shown to be down regulated in ovarian tumor 
[135] "and to reduce cell proliferation in response to FGF2 when ectopically 
expressed in the ostecosarcoma cell line, MG-63" [134]. 
6q26:   
Loss of the long arm of chromosome 6 is well-known genetic alteration in 
melanoma[4-6, 24, 25]. Yet, few drivers have been pinpointed in this region of loss. 
One of the melanoma biomarkers in this chromosomal arm is MYB (6q23) that is 
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used in FISH assays[7]. Here,  rather than detecting the broad loss of the chromosome 
6q that is known in melanoma, a high significant of deletion in a narrow region was 
detected (in fact, the broad deletion of 6q was reported in the GISTIC figure 16, but 
another higher and smaller peak emerged from that broad deletion, which is 6q26, 
indicating that this small deletion is the most significant minimal deletion in 6q) This 
region 6q26 contains the tumor suppressor gene PARK2. Inactivation of  PARK2 due 
to copy number loss has been identified in various human cancers including 
esophageal adenocarcinoma, glioma, non-small cell lung cancer, lung 
adenocarcinoma, ovarian cancer, pancreatic adenocarcinoma, and in skin cutaneous 
melanoma (3.5%) (reviewed in [136]). The copy number loss is the primary mode of 
alteration that  inactivate PARK2 [137]. This gene was studied  as an important tumor 
suppressor gene for several reasons;  First, its frequent deletion in many cancer, as it 
was mentioned above. Second, it is involvement in many crucial cellular process and 
pathways, such as controlling the cell cycle progression. A study on a large group of 
tumors has reported the PARK2 as master regulator of G1/S cyclins, where it 
mediates the coordination of different classes of cyclins and therefore regulating the 
cell cycle. The study showed that PARK2 targets cyclin D and cyclin E for 
degradation, therefore  inactivation of  PARK2 results in the accumulation of of 
cyclin D and acceleration of cell cycle progression[137](similar function to 
CDKN2A). Moreover, the mRNA and the protein expression of  PARK2 have been 
shown to be downregulated in many different cancers, and the low mRNA expression 
correlates with increased lymph node metastasis, higher tumor grade, and worse 
overall survival in ccRCC [136].   
The other gene that was reported in this narrow deletion is PACRG, which is located 
670 bp upstream of  PARK2 and transcribed from the opposite DNA strand. PACRG 
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has been shown to be downregulated in leukemias, glioblastoma, and astrocytic 
tumors [138]. A study on ccRCC has reported that the mRNA and protein expression 
of PACRG and PARK2 together was significantly downregulated compared with the 
nonmalignant tissue [138].  
So, this focal deletion in our study, different than the large deletion of chromosome 6q 
that is frequently detected in melanoma, seems to be important in cancer 
development.  
 
11q13.1:    
Deletion of  chromosome 11q is commonly known in melanoma [4, 22, 24, 139] and 
other types of cancers such as breast cancer [140], lung cancer [141], and 
neuroblastoma [142]. Different studies and biological evidences support the existence 
of melanoma tumor suppressor genes on chromosome 11q, and deletion of this 
chromosome in melanoma has been reported to be associated with advanced tumor 
stage, younger age at presentation, poorer prognosis, and metastasis to the brain [139]. 
In our study, a focal deletion of ~94 kb region was defined in this chromosomal arm.  
This narrow region contains the ovarian tumour domain-containing Ub aldehyde-
binding protein 1 (OTUB1). OTUB1 is expected to play broad functions in cells 
[143]. However, a recent study has shown that Otub1 is positive regulator of the 
tumor suppressor p53 [144]. The study showed that Otub1 plays a critical role in p53 
stabilization and activation in cells in response to DNA damage, and that through 
suppression the MDM2-mediated p53 ubiquitination. Further, overexpression of 
Otub1 results in marked apoptosis and inhibition of cell proliferation in a p53-
dependent manner. Also, Inhibition of Otub1 markedly impaired p53 activation 
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induced by DNA damage [144]. Therefore, a recent review article concluded that 
Otub1 may act as a tumor suppressor, and more studies are needed to determine if 
Otub1 is downregulated in human cancers[143].   
2p21: 
This deletion centered on the gene PKDCC, which has a developmental role [145] but 
no suspected significance in cancer.  It also overlaps a portion of a long noncoding 
RNA LOC102723824, which has not been characterized.  Interestingly, this region 
includes the first exon of EML4.  Multiple fusion products of EML4 and ALK have 
been characterized in non-small cell lung cancer[146-149].  
5q35.3:   
Although several genes fall within this region, few may be of interest in cancer.  
SQSTM1 is an activator of NF-kB [150], which plays a complex role in cancer 
etiology.  It is thought that early inhibition of NF-kB may help cancer cells evade the 
immune system, although late inhibition is known to promote cancer cell survival 
[151, 152].  
Deletions on chromosome 5 do not seem to be a common genetic alteration in 
melanoma. One study has observed deletion of chromosome 5q in melanoma, but 
indicated that deletion of this chromosome has not been associated with harboring any 
putative TSGs in melanoma [32].  However, loss of this region (5q35.3) has been 
reported in a number of tumors such as non-small cell lung carcinoma [153], and 
breast tumors [154] , which implies the potential importance of genes within these 





Deletion of chromosome 6p has been reported in various types of tumors [155]. Yet, 
this is not true in melanoma, where amplification of this Chromosomal arm  is well-
known, as mentioned above. However, here, a very narrow focal deletion was 
reported, spanning only one gene, MAS1L. This deletion does not overlap with the 
amplified region that was reported here (6p24.3).  Interestingly,  homozygous deletion 
at 6p22.1 has been shown in different cancers such as gliomas [155] and high frequent  
LOH of this region was reported in cervical cancer [156]. Although MAS1L does not 
seem to have a known role in tumorigenesis, frequent deletion of this region in 
different cancers suggest a potential importance for genes in this region.  
5p15.33: 
As was mentioned above, deletions on chromosome 5 in melanoma is not common. 
However, here, a very interesting minimal region of deletion was identified on the 
chromosome 5p. Since deletion or LOH of 5p15 is common in different cancers 
[157], several studies aimed to identify the minimal deletion of this region. A study on 
sporadic gastric carcinomas found high frequent LOH at 5p15.33, and an obvious 
genotype-phenotype correlation on 5p15.33 was observed [158]. Moreover,  other 
studies on cervical carcinoma and sporadic colorectal cancer have reported ( through 
detailed deletion mapping on 5p) 5p15.3 as the minimal deletion on 5p [159, 160].  
Further, 5p15.3 has been proposed to contain on or more tumor suppressor 
genes[157]. In our study, this narrow region (1.05Mb) was reported harboring 18 
genes, 3 of which are important putative tumor suppressor genes AHRR, SDHA, and 
NKD2.   
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ARHH: a study has reported AHRR as a tumor suppressor gene in multiple human 
cancers. This study found a consistent downregulation of AHRR mRNA in human 
malignant tissue from different origins including colon, breast, lung, stomach, cervix 
and ovary. Moreover, they found that silencing of ARHH enhances tumor growth in 
vitro and in vivo through deregulation in cell cycle control and protects against 
apoptosis and enhances angiogenic potential, migration and invasion in tumor cells. 
Furthermore, ectopic expression of AHRR resulted in growth inhibition and reduced 
angiogenic potential. The study concluded that AHRR plays an important role in 
suppressing tumor formation in humans[157]. 
SDHA: a study on paraganglioma (known with RET mutation) has reported SDHA as 
a tumor suppressor gene. SDHA is not well studied, but the study, through 
immunohistochemistry and transcriptome analysis, indicated that SDHA acts as a 
tumor suppressor gene through activation of pseudo-hypoxic pathway[161]. 
NKD2: in a very recent study on osteosarcoma (OS), NKD2 was shown to be a 
negative regulator of WNT signaling pathway. The study showed that decreased 
expression of NKD2 is associated with highly aggressive OS state. Also, 
overexpression of NKD2 in metastatic human and mouse OS cells significantly 
decreases cell proliferation, migration, and invasion ability in vitro and significantly 
diminishes OS tumor growth and metastasis in vivo. Therefore, the study showed 







Loss of chromosome 16q, and particularly 16q23 has been reported in different 
cancers [163-165]. In melanoma, different studies have shown loss of 
chromosome16q [6, 166]. Moreover, a CGH study on primary and metastatic 
melanoma has reported the loss of this minimal deletion of 16q23, but no gene was 
specified in this region [167]. In our study, chromosome 16q was reported with a 
focal deletion centered at the 16q23.3 band. This narrow region harbors the putative 
tumor suppressor gene CDH13,, and two non-coding genes has-mir-3180 and MIR 
3182. The involvement of CDH13 in various cancers was reviewed recently by 
Andreeva and Kutuzov [168]. Downregulation of CDH13 has been reported in broad 
range of cancers, including melanoma cell lines, and undetection of CDH13 transcript 
in all examined breast cancer and most other cancer cell lines supports its role as a 
tumor suppressor. Further, the review discussed association between downregulation 
of CDH13 and poor prognosis in various carcinoma. CDH13 re-expression in most 
cancer cell lines inhibits cell proliferation and invasiveness, increase susceptibility to 
apoptosis, and reduce tumor growth in vivo models.  Reporting this minimal deletion 
containing CDH13 as the most significant loss in chromosome 16q across the 
melanoma samples in our analysis might imply the importance of this gene in 
melanoma tumorigenesis.   
17q11.2:  
This is a well-known frequent region of deletion in different cancers, and that because 
it harbors the well-known tumor suppressor gene NF1( the RAS inhibitor) [169]. NF1 
is the gene that encodes RAS GTPase-activating protein, so affecting this gene by 
deletion or mutation affects RAS-MAPK signaling pathway [170]. NF1 has been 
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reported to work as a tumor suppressor in melanoma [171]. Loss of NF1 function in 
melanoma has been shown in several studies [170, 172]. These findings confirm the 
frequent inactivation of the NF1 tumor suppressor in melanoma. 
12q24.31:  
This is focal deletion was reported on chromosome 12q, which has been found to be 
amplified in melanoma [22]. Yet, this particular region of deletion (12q24) has also 
been reported in melanoma [167, 173], which indicated the tendency of this region to 
be lost in melanoma cells. In our results, this minimal deletion was reported 
containing NCOR2 gene. Interestingly, NCOR2 (which known as SMRT) is a tumor 
suppressor that has been reported in different cancers. SMRT was shown to be 
involved as a novel tumor suppressor in non-Hodgkin lymphomas [174]. Also, down-
regulation of SMRT in multiple myeloma has been shown to  jeopardize several gene 
functions that play an important role in apoptosis, therefore, restoration of SMRT 
activity might correct the overexpression of antiapoptotic genes [175]. Lastly, a recent 
study has reported that SMRT is an activator of p53 transcription [176]. 
20q11.21: 
Here, a very short region of deletion in the chromosome 20q was reported. This short 
deletion contains just one gene called BPIFB1, Known also as LPLUNC1. Recent 
study has reported this gene to act as an important tumor suppressor gene in NPC 
(Nasopharyngeal Carcinoma) [177]. The study reported that "LPLUNC1 inhibited 
NPC cell proliferation in vitro and tumor formation in vivo. LPLUNC1 also delayed 
cell cycle progression from G1 to S phase and inhibited the expression of cyclin D1, 
cyclin-dependent kinase 4 (CDK4) and phosphorylated Rb. LPLUNC1 inhibited the 
expression of certain mitogen-activated protein (MAP) kinases (MAPK) kinases and 
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cell cycle-related molecules. Western blotting confirmed that the expression of 
MEK1, phosphorylated ERK1/2, phosphorylated JNK1/2, c-Myc and c-Jun were 
inhibited by LPLUNC1, suggesting that the MAPK signaling pathway is regulated by 
LPLUNC1 [177]. Another 2014 study reported that LPLUNC1 inhibit NPC cell 
proliferation through inactivation Stat3 "Induction of LPLUNC1 overexpression 
inhibited NPC cell proliferation, induced NPC cell arrest, promoted NPC cell 
apoptosis even after IL-6 stimulation and inhibited the growth of implanted NPC 
tumors in vivo, which were associated with decreasing cyclin D1 and Bcl-2 




The gene SH3BGRL2 is an paralog to SH3BGRL.  While the latter has been shown to 
contribute to Rel-mediated transformation when inactivated [179],  so such role has 
yet been identified in the former.  
10q23.2:   
10q is known deletion in melanoma [4].  Loss of 10q23 is common in melanoma and 
loss of this region (more specifically 10q23.3) has been associated with inactivation 
of the tumor suppressor gene PTEN in melanoma [4, 180, 181]. The PTEN gene was 
not among genes reported in this peak. Yet, deletion of this region in our analysis 
emphasizes the tendency of this region to be deleted in melanoma. 
This region also contains the last exon of WAPAL, a gene which is a component of 
the cohesin complex.  Loss of WAPAL function potentially prevents the release of 




Only one gene was reported at this focal deletion, which is the potassium channel 
subfamily M regulatory beta subunit 1, KCNMB1. There is no known importance of 
this gene in oncogenesis. However, this region has been reported to be frequently 
deleted in lung cancer, indication the presence of important genes with tumor 
suppression function at this region[153, 184, 185].  
16p13.3 :  
Deletion of 16p has been reported in melanoma [25, 186]. Here, a small (~752 Kb) 
telomeric deletion that contains 40 genes (some of them are non-protein coding 
genes). Here, at least two known tumor suppressors can be identified: AXIN1 and 
ARHGDIG.  
AXIN1: is a WNT pathway tumor suppressor that is essential for beta catenine 
degradation, and it is inactivation has reported in various tumors[187, 188]. 
Furthermore, AXIN has been shown to act as a tumor suppressor through stimulating 
the p53 function [189]. 
ARHGDIB:  is a metastasis suppressor that has been shown to contribute to cancer 
cell invasion and metastasis, and also has been shown to be involved in mouse 
melanoma B16 cells [190]. 
13q13.3: 
Deletion of this particular region 13q13.3 has been reported in different cancers such 
as breast cancer [191, 192], and lung cancer [193]. Here, this region was reported with 
one gene DCLK1. Some studies have reported deletion of this region with this gene 
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such as in testicular primary seminoma [194], and in pleomorphic sarcoma of bone 
[195]. A study on melanoma has reported a large deletion of 13q12-34 [166]. 
3q13.31: 
ZBTB20 is involved in NF-kB signaling and promotes the innate immune response 
[196] (cf. SQSTM1 also deleted).  It is also a negative regulator of Sox9 [197].  Sox9 
has been shown to induce cell cycle arrest and apoptosis in melanoma via antagonism 
of Sox10 [198].  Therefore, deletion of Sox9 has the potential to promote melanoma 
initiation and progression.   
10p15.3: 
Loss of 10p15.3 is a common deleted region in different cancers including colorectal 
cancers [199] and lung cancer [184]. In melanoma, loss of 10p is common genetic 
alteration (with loss of 10q as well as loss of the whole chromosome) [4, 32, 200]. 
Microarrays studies on melanoma have reported deletion of 10p15.3 [32, 181]. In our 
study, this region of deletion was reported with the the RNA editing enzyme gene 
ADARB2. ADARB2 RNA level has been reported to be 99% decreased in brain 
tumors and ADARB2 reduction correlates with grade of malignancy of glioblastoma 
multiforme, the most aggressive form of brain tumors [201, 202]. 
3p22.1: 
This is a very narrow deletion centered at the gene VIPR1. This region of deletion is 
common in non- small cell lung cancer [203]. VIPR1has been reported to be a tumor 
suppressor in lung adenocarcinoma, where it is significantly downregulated, and 




This deletion encompasses the entire gene ACOT11, a lipid transfer protein.  
ACOT11 has been shown to be significantly methylated in bladder cancer, and the 
degree of methylation was associated with tumor stage [205, 206].  Any specific 
biological function of ACOT11 in cancer remains to be determined. 
11p15.4: 
This region is adjacent to a domain on 11p15.5 known to play a role in Wilms and 
rhabdomyosarcoma [207], adrenocortical carcinoma[208], and lung[209], 
ovarian[210] and breast cancers [211]. Interestingly, 11p has been reported with 
reduced copy number in melanoma[24]. 
21q22.3: 
Loss of 21q22.3 has been shown to be associated with melanoma [212].  Within this 
large deletion, the transient receptor potential channel gene TRPM2 has been shown 
to increase the susceptibility of melanoma to apoptosis and necrosis [213].  An 
antisense transcript of TRPM2 is up-regulated in melanoma (ibid).  Intriguingly, the 
related gene TRPM1 (melastatin, at 15q13.3) has been known to be downregulated in 
highly metastatic melanoma [214].  21q22.3 deletion is also observed in prostate 
cancer [215].   
18p11.31: 
Here, only one gene was reported, LAMA1. It is one of the genes that encode 
laminins, which are major proteins  in the basal lamin. They influence cell 
differentiation, migration, and adhesion. Also they can play a role in invasive 
behavior of tumor cells [216]. LAMA1 has been reported to be hypermethylated and 
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underexpressed in pancreatic tumor samples compared to normal samples [217]. 
Moreover, downregulation of LAMA1 has been reported in ovarian cancer cell 
lines[216]. 
1q21.3: 
This deletion is almost exclusive to the gene KCNN3 (SK3).  This potassium channel 
is better known for its role in neuron firing, but it has also been shown to play a role 
in the motility of breast cancer [218] and melanoma [219] cells.  It was shown that 
KCNN3 was not expressed in normal melanocytes, but that induced expression of 
KCNN3 in melanoma cells increased migration.  This work was done in cultured 
melanoma cell lines; the frequency of SK3 overexpression in melanoma is unknown 
in situ, but our data would suggest that SK3 overexpression could be an artifact of cell 
culture.   
2p21: 
This deletion includes the last exon of PPM1B.  PPM1B is thought to act as a 
phosphatase toward IKK, thereby attenuating the activity of NF-kB [220].  This 
locus as a whole is involved in 2p21 Deletion Syndrome (OMIM #606407), which is 
not known to contribute to an elevated prevalence of any cancers.  
9p21.3: 
 Although deletion of chromosome 9 was also reported in our result, a more focused 
(expected) deletion was also reported in chromosome 9 centered at 9p12.3. This 
region contains the well-known tumor suppressor gene CDKN2A, and other tumor 
suppressors such as CDKN2B, MTAP and ELAVL2. CDKN2A is the one of the  
highest-penetrance melanoma susceptibility gene [69, 70] and it is deletion or loss of 
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expression in melanoma is well-known [69, 70, 221, 222]. As it was mentioned 
above, other important genes are  also located in this region. CDKN2B is one of the 
genes located at 9p21 and has been shown to be deleted in melanoma [6, 223] and 
other cancers such as cutaneous T-cell lymphoma [224]. Interestingly, codeletion of 
cluster of genes involving CDKN2A, CDKN2B, MTAP and in some cases ELAVL2 
has been shown in different cancers. For instance,  deletion of CDKN2A, CDKN2B, 
MTAP and ELAVL2 in myeloid leukemia [225] and CDKN2A, CDKN2B and MTAP 
in B- lineage acute lymphoblastic leukemia [226], head and neck squamous cell 
carcinoma [227], mesotheliomas [228] and in glioblastoma [229]. Deletion of this 
large 9p21 segment is a frequent genetic alteration in variety of cancers causing 
inactivation of critical tumor suppressor genes and therefore plays a very important 
role in development of many human cancers, including melanoma [230, 231]. Our 
result confirms the frequent involvement of 9p21 deletion in melanoma samples. 
However, 9p21 is not a high discriminatory loci, where it is heterogeneous deletion 
can also be seen not just in melanoma but in melanocytic nevi as well. In contrast, 
homozygous deletion of 9p21 seems to be more associated in melanoma [49, 232]  
22q13.32: 
This deletion encompasses over 150 annotated genes, and is frequently deleted in 
human breast and colon cancers [233].  Within this region are at least three genes with 
some demonstrated connection to cancer: BIK, PRR5, and PANX2.  BIK is an 
important player in the activation of Bax to induce apoptosis, and has been found to 
be deleted in several human cancers [234].  Interestingly, overexpression of Bik 
induces apoptosis in melanoma cells, and BIK expression in a xenograft model 
delayed melanoma tumor growth [235].  PRR5 is suspected tumor suppressor gene in 
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breast cancer [233] and a component of mammalian target of rapamycin complex-2 
(MTORC2) [233] although little is known about its function.   PANX2 acts as a tumor 
suppressor in glioma cells [236].  The related pannexin family members PANX1 and 
PANX3 show reduced expression in basal and squamous cell carcinomas [237]; 
however, PANX1 may be a driver of melanoma [238].  Much remains to be 
understood about how these pore channel proteins play roles in tumorigenesis.  
22q13.32 has also been found deleted in 25% of fibrolamellar hepatocellular 
carcinomas [239]. 
2q33.2: 
Two caspases falls into this region.  CASP8 lies just downstream of death receptors in 
the cell-extrinsic apoptosis pathway.  As such, it has been found to be mutated or lost 
in many cancers (reviewed in [240]).  CASP10 mutation has been observed in gastric 
cancer [241], non-Hodgkin’s lymphoma [242].   
RAPH1, also found within this deletion, is also deleted in oral squamous cell 
carcinoma[243], head and neck squamous cell carcinoma [244], esophageal squamous 
cell carcinoma [245], lung cancer [246], and neuroblastoma [247].  Reduced 
expression is found in breast and ovarian [248].  
ABI2 also found in this region. Many Studies have reported ABI2 as a tumor 
suppressor, where Abi2 promotes Abl-mediated phosphorylation of Cdc2 and 
inactivation of Cdc2 kinase activity, leading to suppression of cell growth [249, 250]. 
13q34: 
This deletion has been observed previously in several cancers, but not to our 
knowledge in melanoma.  Notably, 13q34 is lost in 45% of cutaneous anaplastic large 
cell lymphoma [251],  67% of chronic lymphocytic leukemias [252], and 8% of 
Burkitt lymphomas [253].  It has also been noted missing in some cervical squamous 
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cell carcinomas [254-256], breast cancer cases showing centrosome abnormalities 
[257], one case of chronic lymphocytic leukemia [258], esophageal squamous cell 
carcinoma [259], bladder carcinoma [260], and cutaneous T-cell lymphomas [256].  
Among the genes found in this region are ING1, COL4A1, and COL4A2.  ING1 is 
downregulated or lost in several cancers [261, 262]  ING1 (Inhibitor of growth 1) is a 
well-known tumor suppressor that is known to be involved in cell growth control, 
apoptosis, cell proliferation, senescence, and DNA replication and repair [262-264]. 
COL4A1 and COL4A2 are suspected tumor suppressor genes [260]. 
15q26.1: 
SLCO3A1, found here in its entirety, is another known regulator of NF-kB [265] 
(along with PPM1B, SQSTM1, and ZBTB20) deleted in our melanoma specimens.  
Overexpression of SLCO3A1 was shown to induce NF-kB transcriptional activity 
(ibid).  It has also been suspected of serving to transport anticancer drugs out of the 
cell [266], but this has not been demonstrated to our knowledge.  Deletion of 
SLCO3A1 has been observed in acute lymphoblastic leukemia [267].  
 Chromosome 9: 
This peak (with the highest q value) represents loss of the entire chromosome 9. The 
incidence of this genetic alteration is frequent in bladder cancer [268, 269].  CGH 
study on  primary cutaneous melanoma by Bastian et al has reported the loss of 
chromosome 9 in melanoma samples [25]. Moreover, another study on sporadic and 





Illustrating  the potential of GISTIC and it is propensity to detect driver events  is that 
it is able to recognize regions of amplifications and deletions that are highly 
associated with melanoma and have been reported in several melanoma studies. For 
example, recognizing the amplification of 1q, 6p24 and 8q24 with deletion of 8p, 
6q26, 11q, 12q24, 10q23.3, 21q22.3, all of 9, and 9p21.3. Furthermore, the identified 
regions we found contain almost all cancer genes known to be associated with 
melanoma. Identifying these previously known copy number changes in melanoma in 
our analysis as statistically significant copy number events indicates the reliability of 




GISTIC analysis reveals novel genes potentially involved in melanoma. 
A major advantage of GISTIC is its ability to find and report the minimal regions of 
change that are highly and frequently altered against the broad somatic copy number 
changes, which is frequent in melanoma. These statistically significant focal regions 
of amplifications and deletions imply the importance of genes within these regions. 
GISTIC analysis revealed three high significance of amplifications in very narrow 
regions, each region contains only one gene, and forth region potentially contains a G-
protein coupled receptor called NPSR1 (Table 6). These regions of amplification have 
not been reported in primary melanoma specimens before. As was discussed above, 
all of these genes have been found to be amplified in various cancers, which indicates 
their importance in cancer pathogenesis. Furthermore, GISTIC analysis revealed at 
least 10 regions of significant deletions that have not been characterized in melanoma 
97 
 
before. Some of these regions are within regions that have been reported in melanoma 
as broad chromosomal copy number changes (Table 6). Most of the genes involved in 
these focal deletions are known tumor suppressor genes in various cancers.  
 




Gene Function   
7p14.3 NPSR1 G protein-coupled receptor.   
10q11.21 RET Receptor tyrosine kinase, proto-oncogene.   
11q14.1 DLG2 Membrane-associated guanylate kinases.   







4p16.3 FGFRL1 Putative tumor suppressor in bladder cancer. 
5p15.33 SDHA Putative tumor suppressor in paraganglioma. 
5p15.33 AHRR Tumor suppressor gene in multiple human cancers 
5p15.33 NKD2 negative regulator of WNT signaling pathway. Putative TS IN OS.  
6q26 PARK2 Tumor suppressor gene in multiple human cancers. 
6q26 PACRG Putative tumor suppressor gene. 
8p23.2 CSMD1 Tumor suppressor gene in multiple human cancers. 
11q13.1 OTUB1 Positive regulator of p35, Putative tumor suppressor.  
12q24.31 NCOR2 p53 transcription activator, tumor suppressor. 
13q34 ING1 Tumor suppressor gene in multiple human cancers. 
13q34 COL4A1 Suspected tumor suppressor gene. 
13q34 COL4A2 Suspected tumor suppressor gene. 
16p13.3 AXIN1 p53 activator and WNT pathway tumor suppressor. 
16p13.3 ARHGDIG Metastasis suppressor 
16q23.3 CDH13 Putative tumor suppressor. 
20q11.21 LPLUNC1 Tumor suppressor gene in Nasopharyngeal Carcinoma. 









IIII. CONCLUSION AND SIGNIFICANCE. 
 
Thus, GISTIC provided a robust and unbiased analysis to identify somatic copy 
number alterations in melanoma samples. The identified regions of aberrations 
represent the most statistically significant differences between the clinical melanoma 
and benign nevi specimens. Therefore, these results can be exploited to improve 
current diagnostic techniques and provide more sensitive techniques to discriminate 
between problematic melanomas and benign nevi neoplasms. Moreover, GISTIC 
detected key genomic regions whose genes seem to play important role in melanoma 
pathogenesis. Some of these novel identified genes (especially in significant region of 
amplifications) are potential candidates for molecular targeted therapies. In fact, 
proposed therapies have been introduced targeting some of the novel genes identified 
in our analysis, such as targeting the RET gene with small receptor tyrosine kinase 
inhibitors in thyroid cancer (specifically for identified activating mutations in RET) 
and other cancers [271-273]. Another gene that is being targeted for cancer therapy is 
ERG transcription factor, the gene with the most significant copy number gain in our 
analysis. Several studies have reported their attempts in developing drugs that target 
the ERG transcription factor, mostly in prostate cancer [274, 275].   
Further work is needed to validate these findings and test their potential to be 
implicated in current diagnostic tools. These findings were obtained from examining 
actual clinical specimens, which indicates the high potential of considering these 
results to improve current diagnostic techniques for differentiating melanoma from 
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